Today's News and Commentary

About the public’s health

Covid-19 Vaccines Won’t Come With Copays, U.S. Health Official Says:”The U.S. government will pay for the vaccines and their distribution, and is working with commercial health insurers to offer the shots free of charge and without a copay, according to Paul Mango, deputy chief of staff for policy at the U.S. Department of Health and Human Services.”

2020’s Best & Worst States for Health Care: WalletHub’s annual report. At the top are Massachusetts and Minnesota. At the bottom are Georgia and Louisiana. Read the full article for the methodology.

HHS invests $6.5 million in diagnostic labs to expand COVID-19 testing:”The U.S. government is investing $6.5 million in two diagnostic laboratories to increase the country’s COVID-19 testing capacity and perform an additional 1 million tests each week by early October. 
The U.S. Department of Health and Human Services (HHS) said on Thursday the funding would enable the selected companies - Aegis Sciences Corp and Sonic Healthcare USA, a unit of Sonic Healthcare Ltd - expand capacity by increasing staffing and infrastructure.”

Top U.S. health official says COVID vaccines unlikely to be approved before November: NIH director Francis Collins “does not believe any potential COVID-19 vaccines backed by Operation Warp Speed are unlikely to be approved before November or December, given the time needed for large-scale clinical trials…”

Guideline: The American Thoracic Society provides recommendations on initiating pharmacologic treatment for tobacco-dependence: “The guideline panel formulated five strong recommendations and two conditional recommendations regarding pharmacotherapy choices. Strong recommendations include using varenicline rather than a nicotine patch, using varenicline rather than bupropion, using varenicline rather than a nicotine patch in adults with a comorbid psychiatric condition, initiating varenicline in adults even if they are unready to quit, and using controller therapy for an extended treatment duration greater than 12 weeks. Conditional recommendations include combining a nicotine patch with varenicline rather than using varenicline alone and using varenicline rather than electronic cigarettes.”

Systematic review with meta-analysis of the accuracy of diagnostic tests for COVID-19:

The takeaways:

RT-PCR followed by CT shows high sensitivity for detecting COVID-19.

Immunological tests should use a combination of IgG and IgM.

The genes E and RdRp present high analytical sensitivity to detect the virus.

Assays for molecular diagnosis should employ 2-target systems.

Studies of diagnostic tests for COVID-19 are of moderate methodological quality.

RT-PCR remains the gold standard for the diagnosis of COVID-19 in sputum samples. However, the combination of different diagnostic tests is highly recommended to achieve adequate sensitivity and specificity.

Mental Health, Substance Use, and Suicidal Ideation During the COVID-19 Pandemic — United States, June 24–30, 2020: From the CDC: “Overall, 40.9% of 5,470 respondents who completed surveys during June reported an adverse mental or behavioral health condition, including those who reported symptoms of anxiety disorder or depressive disorder (30.9%), those with TSRD symptoms related to COVID-19 (26.3%), those who reported having started or increased substance use to cope with stress or emotions related to COVID-19 (13.3%), and those who reported having seriously considered suicide in the preceding 30 days (10.7%).”

About hospitals and health systems

13 hospital construction projects costing $1B or more: Amazing that there are this many projects of this size given the economy.

Fitch maintains stable rating outlook for US nonprofit hospitals: “Fitch Ratings has maintained its stable rating outlook for US nonprofit hospitals and health systems and said it expects to keep it stable for the remainder of the year. 
While the rating outlook remains stable, Fitch revised the sector outlook to negative in March due to adverse effects from the pandemic and said it will maintain the negative sector outlook. Sector outlooks reflect business and economic conditions and while often correlated with rating outlooks they are more sensitive to changes in the economy.”

About health insurance

Oklahoma withdraws Medicaid block grant proposal: The state was going to be the first to test this method of payment being promoted by Republicans.

Today's News and Commentary

About the public’s health

U.S. reports fewer than 50K new COVID-19 cases for 3rd day in a row: However the large geographic differences remain. Also: American Academy Of Pediatrics: Number Of Coronavirus Cases Among Children In U.S. Has Increased 90 Percent In Last Month. And: U.S. reports highest number of covid-19 deaths in one day since mid-May.

Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial: “Yearly mammography before age 50 years, commencing at age 40 or 41 years, was associated with a relative reduction in breast cancer mortality, which was attenuated after 10 years, although the absolute reduction remained constant. Reducing the lower age limit for screening from 50 to 40 years could potentially reduce breast cancer mortality.”
The problem of false positives remains. As far as cost/benefit, US costs would need to be used since mammograms are much more expensive here.

CareSource pledges $50M to support affordable housing: “Ohio's largest Medicaid managed care provider has pledged to invest millions of dollars to support affordable housing projects across the U.S.
The $50 million investment, announced Tuesday by Dayton-based CareSource, will be spread across its existing markets in Ohio, Indiana, Georgia, Kentucky and West Virginia, as well as new markets as the organization expands its footprint.”

Hahn: COVID-19 vaccine decision will be "deliberative": “The commissioner of the US Food and Drug Administration assured physicians and other healthcare providers that vaccine and therapeutics approvals for the COVID-19 pandemic will be ‘based on good science and sound data.’” Isn’t it sad that we need the reassurance?

Virucidal efficacy of different oral rinses against SARS-CoV-2:Look at Table 1 at the end of the article. The authors concluded that in particular, they “observed that three formulations (products c, e and f) containing different active compounds significantly reduced viral infectivity to undetectable levels.” Listerine cool mint (f) is the most recognizable name on the list.

About healthcare quality

85 hospitals with a 1-star CMS rating for patient experience: Yesterday the 5-star hospitals were referenced. Here is a list of the 1-star hospitals rated for patient experience. It seems to have many institutions that care for underserved populations.

UnitedHealth study: Primary care docs in value-based models achieve better patient outcomes: “Primary care physicians reimbursed in a global capitation model perform better on key quality metrics than those in a fee-for-service model, a new study from UnitedHealth Group shows…
For example, 80% of patients treated in the value-based arrangements were screened for breast cancer, compared to 74% of those in fee-for-service. More than 80% in global capitation were screened for colorectal cancer while 74% of fee-for-service patients were screened…
In addition, the study found that MA members treated in a global capitation arrangement had better blood sugar control levels, were more likely to be administered an eye exam and were provided functional status assessments and medication reviews more frequently.”

About healthcare IT

Health Experts Warn About Perils of New Virus Data Collection System: “Nearly three dozen current and former members of a federal health advisory committee, including nine appointed or reappointed by the health secretary, Alex M. Azar II, are warning that the Trump administration’s new coronavirus database is placing an undue burden on hospitals and will have ‘serious consequences on data integrity.’”

3.1M records tied to medical software company Adit found exposed online:”More than 3 million user records tied to a medical software company called Adit have been found exposed online and may have been stolen by malicious actors.
Discovered by security researcher Bob Diachenko, who revealed it today, the data included full names, email addresses, home and work phone numbers, marital status, sex and medical practice name. The database was completely unsecured with no password or other authentication required to access it.”

About pharma

COVID-19 vaccine players will split $100B in sales and $40B in profits, with Moderna leading the way: analyst: Evercore ISI pharma analyst Josh Schimmer predicted “that the total market for COVID-19 vaccines would be worth $100 billion in sales and $40 billion in post-tax profits. He assumed frontrunner Moderna would supply about 40% of the market, Novavax would take 20% and the other vaccine developers would split the rest.”

About health insurance

Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Laboratory Testing: This site updates the CPT coding for testing for SARS-CoV-2.

Today's News and Commentary

About the public’s health

One in Three Americans Would Not Get COVID-19 Vaccine: Update on the public’s attitude toward a COVID-19 vaccine: ”…many Americans appear reluctant to be vaccinated, even if a vaccine were FDA-approved and available to them at no cost. Asked if they would get such a COVID-19 vaccine, 65% say they would, but 35% would not.
The results are based on July 20-Aug. 2 polling in Gallup's COVID-19 tracking survey…”
The most striking differences are still along political affiliation.

LabCorp COVID tests free for three months to aid plasma donations:”Leading testing company LabCorp is offering a ‘no charge’ antibody COVID-19 testing program in the hope it will boost blood plasma donations.
A number of biopharmas, including the likes of Takeda, are hoping to use donated blood plasma from those who have recovered from COVID-19 and tap their antibodies as a potential therapy for the disease.”

US signs $1.5B deal for 100 million doses of Moderna's coronavirus vaccine candidate:”The U.S. federal government inked an agreement valued at up to $1.525 billion with Moderna Aug. 11 for 100 million doses of its COVID-19 vaccine candidate.
The vaccine candidate, mRNA-1273, will be manufactured while its clinical trials are underway. Moderna is developing the vaccine  with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.”

Facebook says it has taken down 7 million posts for spreading coronavirus misinformation: “Facebook said Tuesday that it took down 7 million posts pushing covid-19 misinformation from its main social media site and Instagram between April and June as the company tried to combat the rapid spread of dangerous information…”

Fauci: 'I seriously doubt' Russia's coronavirus vaccine is safe and effective: The headline speaks for itself.

Comparison of Heart Team vs Interventional Cardiologist Recommendations for the Treatment of Patients With Multivessel Coronary Artery Disease: “The heart team’s recommended treatment for patients with multivessel coronary artery disease differed from that of the original treating interventional cardiologist in up to 30% of cases. This subset of cases was associated with a lower frequency of unanimous decisions within the heart team and less concordance between the interventional cardiologists; discordance was more frequent when percutaneous coronary intervention or medication therapy were considered.”
The article highlights the value of teams over individual decisions.

LabCorp, Quest Diagnostics say turnaround time for COVID-19 test results down to 1-3 days:The headline speaks for itself.

About health insurance

CMS launches new alternative payment model for rural healthcare providers: “The Centers for Medicare and Medicaid Innovation (CMMI) will use the model to test whether seed funding, predictable capitated payments, and operational and regulatory flexibilities will enable rural health care providers to improve access to high quality care while reducing health care costs, according to a release issued Tuesday.”
The initiative is called the Community Health Access and Rural Transformation (CHART).

Humana sues Trump administration over ACA cost-sharing reduction [CSR]payments: “Humana estimates that it [has] nearly $2 million in unpaid CSR payments from October, November and December 2017.”

Dawn of the Virtual Medicare Advantage Plan from Alignment Health : “Alignment will make its virtual plan available to eligible consumers, a plan which emphasizes digital, concierge-style solutions for primary care and specialty care services…
Although the plan promotes virtual care, members will not be restricted to the virtual platform if that is not the most effective channel for treatment. For patient interactions that require face-to-face engagement with a provider, the virtual plan will cover in-person visits.”

OIG’s Top Unimplemented Recommendations: Solutions To Reduce Fraud, Waste, and Abuse in HHS Programs: This annual report from the HHS OIG reviews unimplemented recommendations for all HHS programs, ranging from Medicare/Medicaid/CHIP to the NIH to the Indian Health Service. Well worth at least reviewing the list, which starts on page 4.

Patient and Plan Spending after State Specialty-Drug Out-of-Pocket Spending Caps: High out of pocket charges usually work to discourage unnecessary, discretionary care. However, specialty medications are usually used for serious conditions out of the patient’s control. So it is no wonder that putting caps on patient out-of-pocket spending saves them money and does not cost the plans more. Cost controls in these cases require different strategies (see the section in Chapter 7 covering cost containment strategies for specialty pharmaceuticals).

About healthcare quality

266 hospitals with 5 CMS stars for patient experience: When you read the list, notice the absence of teaching hospitals (except Mayo clinic).

About healthcare personnel

26 states will soon face shortage of ICU doctors: “The most recent update finds that 26 states will soon face shortages in ICU doctors, up from only five last week. Ten states are at risk of running low on critical care nurses. Seven face shortages in doctors trained to work in hospitals. Nine states will not have enough respiratory therapists, up from zero last week. Six states will face shortages in pharmacists.”

About hospitals and healthcare systems

Sentara, Cone Health to form $11.5B system: “Sentara Healthcare and Cone Health plan to merge in a deal that would create a 17-hospital system with more than 2,400 physicians and advanced practice clinicians…
The health systems also operate health plans. Sentara runs Optima Health Plan and Virginia Premier Health Plan, which serve 858,000 members, while Cone Health runs a Medicare Advantage plan with 15,000 members. Mr. Akin said the health systems plan to eventually combine their health plan operations.”

About healthcare IT

MIT’s AI system diagnoses chest conditions on x-rays, but knows when a radiologist could do better: Really interesting AI application. As the article notes: “Radiologists have largely moved past the idea that artificial intelligence is here to replace them. And a new platform released recently is a perfect example of how imaging experts and AI can coexist.”

The most dangerous health IT trends: Insights from 8 execs: Interesting opinions from 8 CIOs ranging from system vulnerability to lack of data integration.

Today's News and Commentary

About the public’s health

Scientists uneasy as Russia approves 1st coronavirus vaccine: “Russia on Tuesday became the first country to approve a coronavirus vaccine, a move that was met with international skepticism and unease because the shots have only been studied in dozens of people…
However, scientists in Russia and other countries sounded an alarm, saying that rushing to offer the vaccine before final-stage testing could backfire. What’s called a Phase 3 trial — which involves tens of thousands of people and can take months — is the only way to prove if an experimental vaccine is safe and really works.
By comparison, vaccines entering final-stage testing in the U.S. require studies of 30,000 people each. Two vaccine candidates already have begun those huge studies, with three more set to get underway by fall.”

Over 100 bln USD to be needed to ensure access to COVID-19 vaccines: WHO chief: “World Health Organization (WHO) director-general Tedros Adhanom said Monday that for the vaccines alone, over $100 billion will be needed to ensure everyone everywhere can access the tools to fight the COVID-19 outbreak, as reported Xinhua.”
By comparison, “$10 trillion that have already been invested by G20 countries in fiscal stimulus to deal with the consequences of the COVID-19 pandemic so far.’”

Citrus Flavoring Is Weaponized Against Insect-Borne Diseases:”Adding a new weapon to the fight against insect-borne illnesses like Lyme disease and malaria, the Environmental Protection Agency on Monday approved a new chemical that both repels and kills ticks and mosquitoes.
The chemical, nootkatone, an oil found in cedar trees and grapefruits, is so safe that it is used by the food and perfume industries.”

Low-cost measurement of facemask efficacy for filtering expelled droplets during speech: Duke researchers have come up with a method to test facemask performance. In short, N95 masks are very effective for the wearer but vented N95 masks do not protect others.. Handmade cotton masks were about as effective as surgical masks. Finally, neck fleece, bandanas and breathable neck gaiters were found to emit a higher droplet count than control tests involving no masks.

Filtration Efficiency of Hospital Face Mask Alternatives Available for Use During the COVID-19 Pandemic: “When new N95 respirators are unavailable, N95 respirators past their expiration date; sterilized, used N95 respirators; and other less common respirators can be acceptable alternatives.” Also, see the accompanying editorial here.

‘A Smoking Gun’: Infectious Coronavirus Retrieved From Hospital Air: “Skeptics of the notion that the coronavirus spreads through the air — including many expert advisers to the World Health Organization — have held out for one missing piece of evidence: proof that floating respiratory droplets called aerosols contain live virus, and not just fragments of genetic material…
A research team at the University of Florida succeeded in isolating live virus from aerosols collected at a distance of seven to 16 feet from patients hospitalized with Covid-19 — farther than the six feet recommended in social distancing guidelines.”

U.S. COVID-19 deaths drop for first time in four weeks:” The U.S. death toll from COVID-19 fell 16% to about 7,200 people last week, the first decline in deaths after four weeks of increases…”

Trends in Adiposity and Food Insecurity Among US Adults:”In this cross-sectional study, the estimated prevalence of food insecurity appeared to increase from 1999 to 2016 and across all levels of adiposity. These results suggest the need for multidisciplinary approaches to address the association between food insecurity and obesity in the US.”

About health insurance

Inadequate Edits and Oversight Caused Medicare to Overpay More Than $267 Million for Hospital Inpatient Claims with Post-Acute-Care Transfers to Home Health Services:”Medicare improperly paid most inpatient claims subject to the transfer policy when beneficiaries resumed home health services within 3 days of discharge but the hospitals failed to code the inpatient claim as a discharge to home with home health services or when the hospitals applied condition codes 42 (home health not related to inpatient stay) or 43 (home health not within 3 days of discharge). Of the 150 inpatient claims in our sample, Medicare properly paid 3; however, it improperly paid 147 with $722,288 in overpayments. Medicare should have paid these inpatient claims using a graduated per diem rate rather than the full payment. Based on our sample results, we estimated that Medicare improperly paid $267 million during a 2- year period for hospital services that should have been paid a graduated per diem payment.”

Humana sues Teva over recalled blood pressure drugs:”Humana filed a lawsuit against Teva Pharmaceuticals over its sale of since-recalled blood pressure medication that contained carcinogenic substances.
In 2018, the FDA said it was recalling valsartan medications because of their contamination with cancer-causing substances. Teva voluntarily recalled its valsartan drugs in 2018 for products distributed as early as October 2015.
In its lawsuit, filed Aug. 7 in the U.S. District Court for the District of New Jersey, Humana aims to recover ‘substantial’ costs the insurer said it incurred from recalling and replacing Teva's generic blood pressure medication for members.”

Costs higher for those who enroll on the ACA's exchanges during special enrollment periods: study:”Researchers at Harvard examined claims data from 2015 and 2016 on about 1.5 million individual marketplace enrollees and found that 20% signed up for plans during a special enrollment period [SEP]. Those people were more likely to be younger, and their costs were 34% higher, according to the study.
Members who enrolled in an SEP had inpatient care costs that were between 69% and 114% higher, and emergency care costs that were between 11% and 19% higher.”

About pharma

CVS, Walgreens & Costco sued for not filling opioid prescriptions: “A Florida mother filed a class-action lawsuit Aug. 6 against CVS, alleging its pharmacies have been wrongfully refusing to fill legitimate opioid prescriptions.
Edith Fuog’s lawsuit alleges that numerous CVS pharmacies have denied the opioid prescriptions she uses to manage the pain from her chronic conditions since 2017. 
The lawsuit claims CVS’ refusal to fill her prescriptions violates the American with Disabilities Act, the Rehabilitation Act of 1973 and the Affordable Care Act. The case was filed as a class-action lawsuit on behalf of the millions of legitimate opioid users nationwide….Ms. Fuog’s case comes after a similar one was recently filed against Walgreens and Costco by California mother Susan Smith.”

About healthcare IT

Fraudulent HIPAA Communications: An Alert from the Office for Civil Rights: The Department of Health and Human Services (“HHS”), Office for Civil Rights (“OCR”) “sent an alert to its listservs regarding fraudulent communications that are being sent to health care organizations around the country. OCR states that it became ‘aware of postcards being sent to health care organizations disguised as official OCR communications, claiming to be notices of a mandatory HIPAA compliance risk assessment.’ The postcards have a Washington, D.C., return address, and the imposter uses the non-existent title description of ‘Secretary of Compliance, HIPAA Compliance Division.’ OCR further explains that these postcards are being addressed to HIPAA Privacy and Security Officers and indicates that recipients should visit a website link, call or email to take immediate action on HIPAA requirements. Importantly, the website link directs individuals to a non-governmental website.”

Today's News and Commentary

About the public’s health

Gates Foundation Teams Up With Vaccine Maker to Produce $3 Covid-19 Shots:”The Bill & Melinda Gates Foundation said it is backing the world’s largest vaccine maker, Serum Institute of India, to churn out 100 million doses of coronavirus vaccine for poorer countries and price them at less than $3.”

New CDC Guidelines Advise People to Wear Masks Without Vents, Valves: “The Centers for Disease Control and Prevention has released new guidance on wearing face coverings during the coronavirus pandemic, advising people not to use masks with vents or valves.” Check CDC mask recommendations here.

Young MSM [men who have sex with men] at high risk for HIV should be screened every 3 months, study suggests: “Screening young men who have sex with men every 3 months for HIV is cost effective and improves clinical outcomes compared with less frequent screening…”

Hospitalization Rates and Characteristics of Children Aged <18 Years Hospitalized with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 1–July 25, 2020: From the CDC: “Analysis of pediatric COVID-19 hospitalization data from 14 states found that although the cumulative rate of COVID-19–associated hospitalization among children (8.0 per 100,000 population) is low compared with that in adults (164.5), one in three hospitalized children was admitted to an intensive care unit…
Children are at risk for severe COVID-19. Public health authorities and clinicians should continue to track pediatric SARS-CoV-2 infections. Reinforcement of prevention efforts is essential in congregate settings that serve children, including childcare centers and schools.”

Scientists in spat over whether to infect people in coronavirus vaccine trials: The headline speaks for itself.

About healthcare technology

FDA approves Guardant’s tumor-sequencing blood test as a Tagrisso lung cancer diagnostic: ”Guardant Health received a milestone approval from the FDA for its cancer test, as the first liquid biopsy able to genetically profile solid tumors anywhere in the body through a single blood draw.|This can provide oncologists with biomarker and mutation information across 55 genes linked to multiple cancers, without needing to remove samples of the tumor tissue—but the Guardant360 CDx test has not been approved to direct patients toward a particular treatment, in all cases.
The agency did, however, grant the test a new, specific companion diagnostic approval for identifying patients with metastatic non-small cell lung cancer, who may benefit from AstraZeneca’s Tagrisso based on the presence of epidermal growth factor receptor, or EGFR alterations.”

FDA clears Siemens’ wheeled, bedside CT scanner: “Placed at a person’s bedside, the Somatom On.site allows for easier head exams of critically ill patients, including those within intensive care units.”

About pharma

Kodak's $765 million manufacturing loan on the rocks as red flags multiply: “The government put the $765 million loan on hold after "allegations of wrongdoing" on the company's part jeopardized its federally funded move into pharmaceuticals, the U.S. International Development Finance Corporation (DFC) said in a terse tweet Friday. “

Novartis to charge $2.1 million for Zolgensma following its US approval as first gene therapy for paediatric SMA patients: “Novartis' AveXis unit announced Friday that the FDA has approved Zolgensma (onasemnogene abeparvovec-xioi) for the treatment of patients under two years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the SMN1 gene. The company noted that Zolgensma is the first gene therapy approved in the US for the treatment of patients with SMA, including those who are pre-symptomatic at diagnosis…
Novartis has priced Zolgensma, which is administered via a single intravenous infusion, at a cost of $2.13 million.”

About health insurance

Kaiser's net income more than doubles to $4.5B in Q2: “After reporting a $1.1 billion net loss in the first quarter, Kaiser Permanente's revenue, operating income and net income for its nonprofit hospital and health plan units increased year over year in the second quarter of this year. 
The Oakland, Calif.-based healthcare giant reported operating revenues of $22.1 billion in the second quarter of 2020, up 3.3 percent from the same period a year earlier. Kaiser also saw expenses decline about 1.5 percent year over year to $20 billion.”

Trump teases order requiring insurers to cover preexisting conditions: President Trump “teased an executive order to require health insurers to cover all preexisting conditions, something already established under the Affordable Care Act, which his administration is suing to dismantle.
’Over the next two weeks I’ll be pursuing a major executive order requiring health insurance companies to cover all preexisting conditions for all companies,’ Trump said during a news conference at his Bedminster property in New Jersey.”

About healthcare IT

VA, Cerner restart $16B EHR overhaul with planned October go-live: “The Department of Veterans Affairs and Cerner are resuming a massive medical records project with a new go-live date in October.
In early April, the VA hit pause on its $16 billion electronic health record overhaul due to the COVID-19 pandemic. The agency is working to transition from its customized VistA platform to a Cerner EHR system.”

Today's News and Commentary

About pharma

Pfizer, Amgen will rake in billions during ‘golden age’ for biosimilars: Analyst:”Pfizer’s global biosim sales grew 36% during the quarter to $289 million, driven largely by cancer drugs. The significance of that growth wasn’t lost on Bernstein analyst Ronny Gal. In a note to investors earlier this week, he singled out Pfizer, along with Amgen, as proof that the U.S. biosimilars industry has entered a ‘golden age.’”
The article details some of the products the companies have and the importance of biosimilars in the marketplace.

About the public’s health

Clinical Course and Molecular Viral Shedding Among Asymptomatic and Symptomatic Patients With SARS-CoV-2 Infection in a Community Treatment Center in the Republic of Korea: A reminder about the infectivity of asymptomatic persons: “Many individuals with SARS-CoV-2 infection remained asymptomatic for a prolonged period, and viral load was similar to that in symptomatic patients; therefore, isolation of infected persons should be performed regardless of symptoms.”

New FDA limits on arsenic levels in infant rice cereals don't adequately protect children, critics say: The content is self explanatory. Links to details are in the article. The question is: How low a level is safe?

Court sides with Trump administration effort to impose ‘public charge’ rule: “A federal appeals court on Wednesday sided with the Trump administration’s effort to implement regulations that make it harder for immigrants to seek permanent residency in the United States if they have relied on public assistance programs.
The split ruling from the U.S. Court of Appeals for the 4th Circuit reverses a lower-court injunction that had blocked the ‘public charge’ rule from taking effect.
The decision comes one day after a different appeals court ruled against the administration in a similar challenge brought by immigrant groups that argue the rule discourages legal immigrants from using any public benefits such as Medicaid, food stamps or housing assistance…
Despite the 4th Circuit’s decision Wednesday, the rule remains blocked for now because of a separate nationwide injunction issued by a New York judge in late July.”

‘It’s Kitchen Sink Time’: Fast, Less-Accurate Coronavirus Tests May Be Good Enough: “The best chance to rein in the sprawling outbreaks in the United States now, experts say, requires widespread adoption of less accurate tests, as long as they’re administered quickly and often enough.”

About healthcare providers

Oak Street Health goes public with $328 million offering: “Oak Street Health officially went public on Thursday with a $328 million initial public offering.
The tech-enabled, value-based care primary care start-up specifically targets Medicare-eligible patients, particularly those in underserved communities…
Backers include Humana, as well as General Atlantic and Newlight Partners.
Oak Street has 54 centers in 13 markets across eight states serving 85,000 patients with about 65% of those patients are under capitation agreements. The company has 2,300 employees including 250 primary care providers.”

Mental health startup Ginger lands $50M backed by Cigna, Kaiser Permanente:”The round, led by Advance Venture Partners and Bessemer Venture Partners, included participation from Cigna Ventures and existing investor Jeff Weiner, executive chairman of LinkedIn, as well as Kaiser Permanente Ventures.
The startup, which delivers evidence-based behavioral health coaching, therapy and psychiatry right from a smartphone, has raised more than $120 million to date.”

Today's News and Commentary

About the public’s health

How the pandemic might play out in 2021 and beyond: A really good article from Nature that uses different scenarios in modeling simulations.

Do Americans Face Greater Mental Health and Economic Consequences from COVID-19? Comparing the U.S. with Other High-Income Countries: Among the comparison findings: “More than 30 percent of U.S. adults reported they’ve been faced with negative economic effects from the coronavirus pandemic, a significantly higher percentage than in any of the other countries. These effects include being unable to pay for basic necessities like food, heat, or rent; using up most personal savings; or borrowing money or taking out a loan.
Rates were also high in Canada (24%) and Australia (21%). Meanwhile, only 6 percent to 7 percent of German and Dutch respondents reported these financial hardships.”

‘Discrepancies’ in California’s case data cast doubt as deaths continue to rise: Yet another case of inaccurate data. “In the past week, daily deaths have increased 20%, while flawed data showed cases were down 17%.”

New University of Chicago center will collect thousands of X-rays, CT scans to aid with COVID-19 research:”University of Chicago Medicine will be home to a new, massive database of medical images from COVID-19 patients that researchers can use to better understand and fight the illness, with support from a $20 million federal grant.
The images — such as X-rays and CT scans — will be collected at the University of Chicago and be open source, meaning they’ll be available to researchers around the world. The mainly virtual center created under the contract with the National Institutes of Health expects to collect more than 10,000 images in its first three months.”

Virus testing in the US is dropping, even as deaths mount: ”An Associated Press analysis found that the number of tests per day slid 3.6% over the past two weeks to 750,000, with the count falling in 22 states. That includes places like Alabama, Mississippi, Missouri and Iowa where the percentage of positive tests is high and continuing to climb, an indicator that the virus is still spreading uncontrolled.”

About hospitals and health systems

Indiana University Health to build $1.6B hospital: Many building projects have been scrapped or put on hold with the COVID-19 pandemic, making this announcement noteworthy. “Upon completion of the hospital, expected in 2026, operations of two IU Health adult hospitals in Indianapolis will be consolidated. 
IU Health said that by combining operations of IU Health Methodist and at IU Health University Hospital, the organization will eliminate costly duplication of high-acuity services.”

About pharma

Trump to order government to buy certain drugs solely from U.S. factories, setting up major shakeup for industry:”President Trump will sign an executive order Thursday directing the federal government to buy certain drugs solely from American factories…
It remains unclear, however, how broadly the order will be implemented — the executive order does not specify what drugs it covers. Instead, the order directs the Food and Drug Administration to decide which medicines will be subject to the new requirements, White House trade adviser Peter Navarro told reporters Thursday.”

New Rare Antibiotic Drugs Get Faster FDA Approval Pathway:”Companies making antibiotics for small patient populations will be able to use smaller, more streamlined clinical trials, the Food and Drug Administration said Wednesday. The guidance gives companies more clarity on what is expected when applying for the faster antibiotic approval process. The pathway is the agency’s latest push to generate more novel antibiotics, which typically aren’t high on companies’ priority lists because they don’t make a lot of money.”

Moderna will charge $32 to $37 for COVID-19 vaccine, CEO says: The headline speaks for itself.

Part D plans don't push beneficiaries to take brand-name drugs over generics: study: “Medicare Part D plans largely design their formularies to encourage use of generics, despite some criticism to the contrary, a new study shows.
Researchers led by a team at the Kaiser Family Foundation and Vanderbilt University analyzed more than 4.1 million Part D plan and product combinations, and found that in 84% of cases only the generic was covered by the insurer.
In 15% of cases, the plan covered both the generic and the brand-name product, according to the study published in Health Affairs.”

Mallinckrodt May File for Bankruptcy, Undercutting Opioid Settlement:”Drugmaker Mallinckrodt PLC said it is considering filing for chapter 11 protection over a clash with U.S. regulators and liabilities stemming from the opioid epidemic, potentially undercutting a proposed opioid settlement with state and local governments.
Mallinckrodt said Tuesday it has been in negotiations with creditors about a potential bankruptcy filing covering the parent company and most of its subsidiaries to address opioid-related liabilities, corporate debts and a dispute with regulators over its Acthar Gel medication.”

About health insurance

Major U.S. Health Insurers Report Big Profits, Benefiting From the Pandemic:”Some of the largest companies, including AnthemHumana and UnitedHealth Group, are reporting second-quarter earnings that are double what they were a year ago. And while insurance profits are capped under the Affordable Care Act, with the requirement that consumers should benefit from such excesses in the form of rebates, no one should expect an immediate windfall.”

Medicare payment rules for 2021: 11 notes for hospital execs: A good summary of the payment rules, some of which have been previously discussed here.

Fraudulent coding led CMS to overpay Cigna $1.4B, Justice Department says: “The U.S. Justice Department accused Cigna of using improper diagnostic codes to artificially inflate reimbursement for its Medicare Advantage plans by $1.4 billion in a lawsuit. 
The 64-page lawsuit, filed Aug. 4 in the U.S. District Court for the Southern District of New York, claimed that from 2012 until 2017, Cigna's HealthSpring unit, which runs Medicare plans, submitted false risk adjustment claims to CMS that led to improper reimbursement increases. The Justice Department accuses Cigna of submitting codes for conditions that its Medicare Advantage members didn't have, weren't recorded in medical records or weren't based on clinical data.”

About healthcare quality

CMS outlines long-awaited changes to hospital star ratings: “The proposed change was tucked into a proposed payment rule released by the Centers for Medicare & Medicaid Services on Monday for outpatient hospital departments and ambulatory surgical centers. The rule touches on the use of latent variable modeling (LVM, which combines and summarizes multiple pieces of information and is used to calculate a hospital's star rating…  
If finalized, the rule would discontinue use of the LVM for quality measure group scores and instead adopt a “simple average of measure scores to calculate measure group scores,” the proposed rule stated. “This method would average the measure scores a hospital reports within a given measure group, which have been standardized, to calculated the measure group scores."
See: Meaningful Measures/Patients Over Paperwork

Today's News and Commentary

About health insurance

Deep red Missouri becomes 38th state to approve Medicaid expansion under Obamacare:”Voters on Tuesday made Missouri the 38th state to approve expanding Medicaid health care coverage to thousands more low-income adults.
Support for the constitutional amendment means that as many as 250,000 more adults could choose to be covered by government health insurance beginning in July 2021, according to estimates from the state auditor.”

CMS Announces a Temporary Policy for Premium Reductions: “…the Centers for Medicare & Medicaid Services (CMS) announced a policy that will allow issuers to offer temporary premium reductions for individuals with 2020 coverage in the individual and small group markets. CMS is providing this additional flexibility to help ensure that consumers struggling to pay their premiums can continue to be covered and receive the care they may need during this time.” Normally premiums are fixed after the start of the year.

About pharma

Blood-thinner with no bleeding side-effects is here: If this medicine pans out it will be a huge blockbuster:
”In a study led by EPFL (Ecole Polytechnique Fédérale de Lausanne) scientists have developed a synthetic blood-thinner that, unlike all others, doesn’t cause bleeding side-effects. The highly potent, highly selective, and highly stable molecule can suppress thrombosis while letting blood clot normally following injury.” The substance is an inhibitor of an enzyme called “coagulation factor XII” (FXII). “The only problem is that the inhibitor has a relatively short retention time in the body: it’s too small and the kidneys would filter it out. In the context of artificial lungs, this would mean constant infusion, since suppressing blood clotting for several days, weeks or months requires a long circulation time.” But researchers are working on a longer-lived version.

Gilead's COVID med remdesivir is scarce and costly, AGs say, urging feds to sidestep its patents: “Unhappy with the price and availability of Gilead’s remdesivir—the only drug with FDA clearance to treat COVID-19—dozens of state attorney generals have called for the federal government to exercise march-in rights to allow for broader production of the medicine.
In a letter to the heads of the FDA, HHS and NIH, 34 attorneys general wrote that Gilead has been unable to ensure “sufficient” supply and has priced the medicine out of reach for many patients who need it. Gilead is charging $3,120 per treatment course for patients with commercial insurance, Medicare or Medicaid, and $2,340 for patients on certain smaller federal programs. 
Federal laws allow the government to sidestep patents if the patent holder received taxpayer support and isn't meeting public health needs, the AGs wrote.”

FDA Updates Purple Book to Include All CBER-, CDER-licensed Biologics:”The FDA has updated its Purple Book to include information on all biologics approved by the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER).”

MedWatch to Manufacturer Program:”The U.S. Food and Drug Administration has discontinued the MedWatch to Manufacturers Program (MMP) as of July 31, 2020. This program allowed participating drug and biologic manufacturers to receive information from the FDA on serious adverse event reports that are submitted directly to FDA by voluntary reporters for new molecular entities and original biologics for the first three years after approval. 
Since the introduction of the FDA Adverse Event Reporting System (FAERS) Public Dashboard in 2017, manufacturers can now directly search and download publicly available information from adverse event reports in FAERS, including adverse event reports submitted voluntarily  to FDA.“

About the public’s health

6 states band together to secure rapid COVID testing: “Bipartisan governors of six states have entered into a first-of-its-kind agreement to jointly purchase rapid coronavirus testing kits.
The governors — from Virginia, Louisiana, Massachusetts, Michigan, Ohio and Maryland — said the goal of the compact is to show private companies that there is significant demand to scale up the production of these tests, which deliver results in 15 to 20 minutes.
The states will also coordinate on policies and protocols regarding the testing technology.”

A 50-State COVID-19 Survey from the The COVID-19 Consortium for Understanding the Public’s Policy Preferences Across States (July): Summary:

  • “Most (63%) people are not getting results within the 1-2 days that would be optimal to aid contact tracing.

  • A substantial minority (21%) of individuals are receiving test results too late (5+ days) to be of any significant assistance in helping to control the spread of COVID-19.

  • The testing challenges are national in scope, with most states reporting a median waiting time of 3 days or more.

  • Waiting times are longer for African Americans (5 days) and Hispanic Americans (4.6 days) compared to white respondents.”

For those affected by dementia, the pandemic has been especially grim: “…there is evidence in some rich countries that the age-specific incidence of dementia is declining, even as the overall prevalence increases as societies get older.”
“… as many as 40% of dementia cases might in theory be delayed or prevented by tackling 12 ‘modifiable’ risk factors.” Among the most important are: smoking, high blood pressure, obesity, hearing loss, a low level of education, diabetes, excessive drinking in middle age, head injuries (also in middle age), and exposure to air pollution in later life.

Johnson & Johnson pledges 100M coronavirus vaccine doses to U.S. for $10 each: The headline speaks for itself.

Ancestry rolls out more advanced DNA testing to flag risk of heart disease, breast cancer: “Ancestry is stepping up its consumer DNA testing using next-generation sequencing developed by Quest Diagnostics.
The family history and consumer genomics company is relaunching its AncestryHealth service with more advanced genetic testing technology to flag cutsomers' risk for developing certain inheritable diseases.
The sequencing-based tests replace Ancestry's previous microarray-based tests, the company said in a release. The tests are physician-ordered, are not diagnostic and have not been reviewed or approved by the Food and Drug Administration (FDA).”

About healthcare IT

Teladoc to take over Livongo in $18.5B digital health deal:”Telehealth giant Teladoc has moved to absorb the digital disease management company Livongo through a deal worth as much as $18.5 billion, reflecting the growing importance of virtual healthcare platforms as the world is caught in the wake of the COVID-19 pandemic.
The massive medtech acquisition takes the crown not two days after Siemens Healthineers announced a $16.4 billion offer for the cancer radiotherapy player Varian Medical Systems.”

Today's News and Commentary

About the public’s health

Pennsylvania suspends requirements for childhood immunizations, and that has pediatricians worried: The Pennsylvania Department of Health quietly announced late last month that it was temporarily suspending requirements for children’s immunizations, a move that could send mixed signals to parents about the importance of preventing disease, and could mark a return for vaccine-preventable diseases like measles, doctors fear.
The coronavirus pandemic has made it difficult for families to make scheduled checkups. In Philadelphia, routine immunizations have fallen substantially since March. As a result, many children in Pennsylvania may not have the required immunizations to enter and attend school this fall.”

Health illiteracy is nothing new in America. But the pandemic magnifies how troubling it is.:This article explains how health illiteracy is causing confusion among vulnerable populations. “Health literacy is not about reading skills or having a college degree. It means you know how to ask a doctor the right questions, read a food label, understand what you’re signing on a consent form, and have the numeric ability to analyze relative risks when making treatment decisions.”

Fauci explains the 'insidious increase' that has officials worried about new COVID surges: “Top infectious disease expert Anthony Fauci, M.D., warned the signs indicate more states could experience serious jumps in COVID-19 cases in the next month, following in the footsteps of a handful of southern states that have been hit with surges of the virus in recent weeks.”

The FDA's list of dangerous hand sanitizers has now grown to more than 100: The headline speaks for itself. The list is here.

3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice: “We describe herein the structure-guided optimization of a series of inhibitors of the coronavirus 3C-like protease (3CLpro), an enzyme essential for viral replication…These results suggest that this series of compounds has the potential to be developed further as antiviral drugs against human coronaviruses.”

The six strains of SARS-CoV-2 :”SARS-CoV-2 mutation rate remains low. Across Europe and Italy, the most widespread is strain G, while the L strain from Wuhan is gradually disappearing. These mutations, however, do not impinge on the process of developing effective vaccines.
The virus causing the COVID-19 pandemic, SARS-CoV-2, presents at least six strains. Despite its mutations, the virus shows little variability, and this is good news for the researchers working on a viable vaccine.”

About health insurance

Proposed Policy, Payment, and Quality Provisions Changes to the Medicare Physician Fee Schedule for Calendar Year 2021: “With the budget neutrality adjustment to account for changes in RVUs, as required by law, the proposed CY 2021 PFS [physician fee schedule] conversion factor is $32.26, a decrease of $3.83 from the CY 2020 PFS conversion factor of $36.09.” Recall that the professional feee is the service RVU (determined by the CPT code) x Conversion Factor. Other changes include expansions in telehealth; refinements in coding for extended visits; supervision of diagnostic tests by certain Non-physician Practitioners (NPPs); clarification that physicians and NPPs, including therapists, can review and verify documentation entered into the medical record by members of the medical team for their own services that are paid under the PFS; allowing teaching physicians to use audio/video real time communications technology to interact with the resident through virtual means; and more.

About pharma

Sanofi, GlaxoSmithKline under investigation for possible carcinogen in Zantac: The U.S. Justice Department launched an investigation into whether Sanofi and GlaxoSmithKline failed to report information about a potential carcinogen to the federal government…”

About healthcare IT

Trump signs order to expand access to telehealth services in rural areas:”U.S. President Donald Trump on Monday signed an executive order expanding access to telehealth services for 57 million Americans in under-served rural areas and elsewhere, after virtual visits soared during the coronavirus pandemic.”

Today's News and Commentary

About health insurance

Cuts to 340B payments are legal, appeals court rules:”An HHS policy that will cut Medicare outpatient drug payments by nearly 30 percent at 340B hospitals in the U.S. is legal, an appellate court panel ruled July 31. The ruling overturns a lower court decision. 
Under the 340B program, eligible hospitals can buy outpatient drugs at a discount. A hospital typically pays  20 percent to 50 percent below the average sales price for the drugs….HHS argued that Medicare should not reimburse hospitals more than they paid to acquire the drugs.”

Health Care Spending and the Medicare Program (July 2020):Perhaps the best comprehensive explanation of annual Medicare spending. It is prepared by MedPAC.

Texas, Other States Lose $479 Million in Obamacare Provider Fees: “The Fifth Circuit Friday upheld the Obamacare provider fee that states pay to the IRS on behalf of Medicaid Managed Care Organizations in order to receive federal reimbursement for MCO payments.
The fee is a valid federal tax that doesn’t violate the U.S. Constitution’s spending clause, it said.”

Florida physician charged in $681M billing fraud scheme: “Dr. Ligotti allegedly served as the medical director for more than 50 addiction treatment facilities and signed more than 135 standing orders authorizing fraudulent tests. In exchange for his signature on the standing orders, he allegedly required the treatment centers to have their patients treated at Whole Health. Some patients were allegedly charged between $10,000 and $20,000 by Dr. Ligotti and Whole Health for one visit.”

CMS Finalizes $750M Medicare Payment Boost for Nursing Homes in Fiscal 2021: “The federal government on Friday finalized a previously proposed rule that will bring a 2.2% Medicare payment bump to the nation’s skilled nursing facilities.”

CMS finalizes 3 payment rules for 2021: 5 things to know: “CMS finalized three Medicare payment rules July 31, including updates for psychiatric facilities, skilled nursing facilities and hospices.”

About the public’s health

Characteristics and Strength of Evidence of COVID-19 Studies Registered on ClinicalTrials.gov: The quality of research studies on COVID-19 has been generally poor. This research was a cross-sectional study using ClinicalTrials.gov information. The researchers “found that despite the marked rise in COVID-19 studies, only 29.1% of those registered in ClinicalTrials.gov have the potential to result in OCEBM [2011 Oxford Centre for Evidence-Based Medicine] level 2 evidence. Of the RCTs, only 29.3% are placebo-controlled, blinded studies. Global decline in new cases could also stall enrollment. Even before results are known, most studies likely will not yield meaningful scientific evidence at a time when rapid generation of high-quality knowledge is critical.”

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19: Researchers “detected SARS-CoV-2 S-reactive CD4+ T cells in 83% of patients with COVID-19 but also in 35% of HD [healthy donors].” Meaning that T cell immunity (not just antibody- producing B cell immunity) plays an important part in fighting COVID-19. It is another potential mechanism for vaccine development. Also, the 35% mentioned means healthy people can have cross reactivity and possible protection from previous exposure to other similar viruses.

6 reasons why COVID-19 medical liability shield critics are wrong: One of the differences between Democratic and Republican proposals for COVOD-19 relief is whether there is a liability exemption for employers whose employees become ill. (The former want the liability, the latter want the exemption.) This article from the AMA is a thoughtful analysis of the issue.

COVID-19 Hospital Data System That Bypasses CDC Plagued By Delays, Inaccuracies: This article is a great summary of how the new reporting system is in trouble. In a related article: CDC director says he wasn't involved in decision to reroute COVID-19 hospitalization data

‘The Biggest Monster’ Is Spreading. And It’s Not the Coronavirus: TB is “the biggest infectious-disease killer worldwide, claiming 1.5 million lives each year.” The point of the article is that TB, HIV infection and malaria, all on the decline, have been making a comeback as resources and attention have been focused on COVID-19.

Here are some updates on COVID-19 testing that offer faster/better or easier testing:
Sorrento Licenses COVID-19 Saliva Test;
90 minute COVID-19 tests: [UK]Government orders 5.8 million DnaNudge kits;
Oxford researchers say new artificial intelligence test could identify coronavirus within one hour;
NIH picks seven COVID-19 diagnostic tests in 'Shark Tank' competition, unlocking $248.7M in scale-up funding; and
FDA authorizes first tests for measuring COVID-19 antibody amounts

Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study: “Compared with the general community, front-line health-care workers were at increased risk for reporting a positive COVID-19 test (adjusted HR 11·61, 95% CI 10·93–12·33). To account for differences in testing frequency between front-line health-care workers and the general community and possible selection bias, an inverse probability-weighted model was used to adjust for the likelihood of receiving a COVID-19 test (adjusted HR 3·40, 95% CI 3·37–3·43). Secondary and post-hoc analyses suggested adequacy of PPE, clinical setting, and ethnic background were also important factors.”

About pharma

Ohio pharmacy board reverses hydroxychloroquine ban: Politics wins out over science: “Ohio's board of pharmacy has reversed its ban on hydroxychloroquine for use in COVID-19 patients and said it will reexamine the issue — just a day after announcing its plan to ban the drug — following a request from Gov. Mike DeWine.
The board had announced July 29 a plan to ban medical institutions from prescribing hydroxychloroquine for use in COVID-19 patients as of July 30, saying it was a "patient safety issue." The drug would still have been allowed in clinical trials.”

The day the music died? FDA fields request to ban background music in DTC ads:”While the petition is lengthy, its argument is simple. Music played in the background during the reading of risks distracts consumers and makes it more difficult to understand and remember those risks.”

About hospitals and health systems

Hospitals must start paying back billions borrowed from government during pandemic: Unlike many PPP “loans,” hospitals received advances on Medicare payments which they will need to start paying back soon. This article is a good discussion of the details and issues behind this upcoming major stress.

About healthcare IT

Healthcare groups cheer House move to overturn ban on nationwide patient identifier: Now if the Senate can agree…
”On Thursday, the U.S. House of Representatives passed the six-bill FY2021 minibus package that includes the Labor-Health and Human Services appropriations bill. As part of the bill, the House approved by voice vote the bipartisan Foster-Kelly Amendment, which strikes Section 510 of the Labor-HHS bill and removes the ban on using federal funding to create patient identifiers.

Allscripts sells EPSi business to Strata Decision Technology for $365M: “EPSi is a provider of financial decision support and planning tools for hospitals and health systems.”

Today's News and Commentary

About health insurance

CMS announces two payment initiatives for COVID-19 drug treatment and counseling:”CMS will make payment available to physicians and providers to counsel patients at the time of COVID-19 testing about the importance of self-isolation after they are tested and prior to the onset of symptoms. The agency is also implementing new procedure codes to allow Medicare and other insurers to identify the use of the therapeutics remdesivir and convalescent plasma for treating hospital inpatients with COVID-19. 
These new codes are being implemented into the International Classification of Diseases Procedure Coding System, ICD-10-PCS. They go into effect on August 1. “

Medicare coverage for Alzheimer brain scans in question:”A big study to help Medicare officials decide whether to start covering brain scans to check for Alzheimer’s disease missed its goals for curbing health care costs, calling into question whether the pricey tests are worth it. 
The results announced Thursday are from a $100 million study of more than 25,000 Medicare recipients. It’s been closely watched by private insurers too, as the elderly population grows and more develop this most common form of dementia, which currently has no cure…
The study missed its goal of curbing hospitalizations by 10% in the year after the scan: Rates were 24% among those scanned versus 25% of the others. 
However, among those scanned, there were fewer hospitalizations for those with Alzheimer’s versus those without the disease.”

Oscar Health unveils $0 Virtual Primary Care program, 2021 expansion plans: “The expansion will bring the startup health plan's geographic footprint to 19 states and 47 markets, pending regulatory approvals…
Alongside the plans to further expand its reach, Oscar unveiled its new $0 Virtual Primary Care, which will offer a slew of digital and in-home services to its individual and family plan members in 10 markets, including Houston, Miami, New York City and Los Angeles, at no cost.”

About the public’s health

Age-Related Differences in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Levels in Patients With Mild to Moderate Coronavirus Disease 2019 (COVID-19): VERY IMPORTANT RESEARCH FINDING THAT CHANGES HOW WE HANDLE THE COVID-19 PANDEMIC: “Our analyses suggest children younger than 5 years with mild to moderate COVID-19 have high amounts of SARS-CoV-2 viral RNA in their nasopharynx compared with older children and adults. Our study is limited to detection of viral nucleic acid, rather than infectious virus, although SARS-CoV-2 pediatric studies reported a correlation between higher nucleic acid levels and the ability to culture infectious virus. Thus, young children can potentially be important drivers of SARS-CoV-2 spread [emphasis added] in the general population, as has been demonstrated with respiratory syncytial virus, where children with high viral loads are more likely to transmit. Behavioral habits of young children and close quarters in school and day care settings raise concern for SARS-CoV-2 amplification in this population as public health restrictions are eased.” 

Yesterday, a reporting problem in New Mexico was provided as an example of what probably nationwide issues getting an accurate assessment of COVID-19. Today, two more reporting problems are in the news:

Florida health department says it doesn't collect COVID-19 healthcare worker death data; former employee says it does and
Missouri COVID-19 data backlog cleared, but delays persist, health officials say 

Observations of the global epidemiology of COVID-19 from the prepandemic period using web-based surveillance: a cross-sectional analysis: “Cases with travel links to China, Italy, or Iran accounted for almost two-thirds of the first reported COVID-19 cases from affected countries. Among cases with age information available, most were among adults aged 18 years and older. Although there were many clusters of household transmission among early cases, clusters in occupational or community settings tended to be larger, supporting a possible role for physical distancing to slow the progression of SARS-CoV-2 spread.”

Use of Chest Imaging in the Diagnosis and Management of COVID-19: A WHO Rapid Advice Guide: “The World Health Organization (WHO) undertook the development of a rapid guide on the use of chest imaging in the diagnosis and management of COVID-19…he rapid guide includes three diagnosis recommendations and four management recommendations. The recommendations cover patients with suspected or confirmed COVID-19 with different levels of disease severity, throughout the care pathway from outpatient facility or hospital entry, to home discharge”

Netflix’s Wellness Programming Is Irresponsible and Misleading: The headline is self explanatory and the article has many examples to back up the assertion.

About pharma

Moderna stock sinks as patent case spurs concern for COVID-19 vaccine:”A patent court has sided with Arbutus Biopharma in its dispute with Moderna, raising concerns that the intellectual property dispute could stymie COVID-19 vaccine development. The news sent shares in Moderna down 9% despite it being unclear whether the patent is relevant to its COVID-19 vaccine. 
The case centers on an Arbutus patent covering lipid formulations for the delivery of nucleic acids. In filing the patent, Arbutus said the technology is based on a ‘surprising discovery.’ Moderna disputed the novelty of the idea and took Arbutus to court on the grounds that it would have been obvious at the time of the invention.
The decision is the third ruling in a series of cases brought by Moderna against Arbutus with mixed, but largely unnoticed, results.”

AstraZeneca, Lilly, GSK and more will share COVID-19 antibody secrets to speed manufacturing scale-up:”Eli Lilly, AstraZeneca, Roche's Genentech unit, Amgen, GlaxoSmithKline and Lilly partner AbCellera can now share manufacturing information that could help speed up coronavirus antibody production, thanks to a business review letter [reported here last week] from the Justice Department's antitrust division…Two things those drugmakers can't collaborate on, though? Production costs and pricing.”

US to pay Sanofi, GlaxoSmithKline up to $2.1B for development, 100M doses of coronavirus vaccine:”The majority of the funding will go to Sanofi, which is developing the vaccine candidate based on recombinant protein-centric technology used in its influenza vaccine. Sanofi is partnering with GlaxoSmithKline to incorporate its adjuvant technology into the vaccine for improved efficacy.
More than half of the funding is apportioned for the vaccine's development, and the rest will go to manufacturing costs and an initial supply of 100 million doses. The U.S. has the option to obtain an additional 500 million doses later on.”

Today's News and Commentary

About the public’s health

Operation Warp Speed: a timeline so far: A good summary of the activity from May 15-July 15. Lots of activity, no results.

Patients Evaluate Visit Notes Written by Their Clinicians: a Mixed Methods Investigation: The majority of patients understand their physician’s notes. This finding runs counter to many claims to the contrary and implications from studies of patient health literacy, The researchers found: “Nearly all patients (96%) reported they understood all or nearly all of the self-selected note, with few differences by clinician type or specialty. Overall, 93% agreed or somewhat agreed the note accurately described the visit, and 6% reported something important missing from the note. The most common suggestions for improvement related to structure and content, jargon, and accuracy.”

Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk: This study from the Netherlands “suggests that MRI screening every 18 months between the ages of 35 and 60 years for women with a family history of breast cancer is cost-effective within the National Institute for Health and Care Excellence threshold for all densities. Higher thresholds would favor annual MRI screening. These outcomes support a change of current screening guidelines for this specific risk group and support MRI screening.”
It is important to look at the numbers they used in their calculations. Among the figures, a Quality Adjusted Life Year was valued at $24, 795.87 while the mammogram cost was $322.09 (both converted form Euros). In the US, the CPT code for an MRI mammogram without contrast with computer aided reading is 77049 (global charge). Perusal of the Medicare fee schedule (https://www.cms.gov/apps/physician-fee-schedule/search/search-results.aspx?Y=0&T=0&HT=0&CT=3&H1=77049&M=1 ) shows an approximate average charge of at least $400 (though some localities are as low as $360s). Commercial rates are undoubtedly much higher. So while the cost/benefit of this imaging works in Europe, our costly healthcare system changes the recommendation to a much less affordable option.

Trump launches "Embers Strategy" in coronavirus hotspots:”The Trump administration is sending increased personal protective equipment, coronavirus test kits and top health officials like Drs. Anthony Fauci and Deborah Birx to coronavirus hotspots across the U.S. as part of a campaign called the ‘Embers Strategy,’ White House officials tell Axios…
Its name, the ‘Embers Strategy,’ is meant ‘to highlight the risk level of “‘embers'‘“to decrease the likelihood of “'fires,'" a senior White House official said.”

57% of New Mexico hospitals didn't report COVID-19 data last week: 4 things to know: The article highlights reporting deficiencies that are probably happening nationwide.

Mapping the Spread of the Coronavirus Outbreak Around the U.S. and the World: Time magazine announced its “one-stop dashboard” to keep track of COVID-19 statistics. One interesting feature is the ability to look at trends in new cases by state.

California cuts off coronavirus aid to two cities that refuse to shut down: The cities weigh the balance of losing state aid versus lost revenue from businesses staying closed.
”At their city council meetings on Monday, leaders in Atwater, a city of 29,000 off Highway 99 in Merced County, and Coalinga, a city of 17,000 in the southwest corner of Fresno County, stood by resolutions they passed this spring allowing all businesses in their communities to reopen.
The Governor’s Office of Emergency Services warned the cities last week that they could collectively lose about $600,000 of federal coronavirus relief unless they come into compliance with state health requirements.”

About pharma

Drug Price Forecast 2020: This monograph is Vizient’s forecast for the coming year. Among the findings are a 3.29 percent increase in hospital pharmaceutical costs and the continuation of specialty drugs as the main driver of increasing prices.

Moderna proposes coronavirus vaccine will cost $50 to $60 per course: “The price is higher than the $19.50 per dose price agreed upon by Pfizer and BioNTech for their experimental vaccine in a pre-order deal with the U.S., Financial Times reported. 
AstraZeneca has signed a deal with some European countries to supply its COVID-19 vaccine at $3 to $4 per dose.”

GlaxoSmithKline employs 'new way of thinking' by using 23andMe's genetic data to launch cancer drug trial:”Early-stage trials for a new cancer drug developed by the two companies are now underway. They developed the antibody drug to block CD96, a protein that causes overactivity of another molecule in malignant tumors.”

AstraZeneca bucks industry trend with rise in first-half profits:”UK drugmaker AstraZeneca has increased first-half revenues and profits, bucking a trend at other large pharmaceutical groups that have begun to suffer from the coronavirus-related global economic slowdown. Revenue for the first six months of the year rose 14 per cent at constant currencies to $12.63bn, the company said on Thursday, while its core earnings per share jumped 26 per cent to $2.01. “

How a secretive Pentagon agency seeded the ground for a rapid coronavirus cure: For the past decade, the Defense Advanced Research Projects Agency (DARPA) has been funding technology aimed at “producing antibodies for any virus in the world within 60 days of collecting a blood sample from a survivor…
DARPA’s antibody program, which is known as the Pandemic Prevention Platform, or P3… has already led to the world’s first study in humans of a potential covid-19 antibody treatment.”
Fascinating article about DARPA and this process.

About health insurance

Trump Administration Continues to Keep Out-of-Pocket Drug Costs Low for Seniors: This article is the CMS announcement that the “average basic Part D premium will be approximately $30.50 in 2021.” Also significant is the previously announced $35 per month cap on spending for insulin.

Cigna saw utilization 'closer to normal' in June, expects similar trends in July despite COVID-19 spikes:”Cigna executives said that health utilization crept back up toward the end of Q2, with June appearing ‘much closer to normal.’
And early trends suggest that trend will continue through July, despite spikes in pandemic cases in several regions across the country. Cigna's utilization rate declined between 30% and 35% in April, but has climbed back up steadily since…”

Healthcare investments

State Of Healthcare Q2’20 Report: Sector And Investment Trends To Watch:
“REPORT HIGHLIGHTS:

  1. Global healthcare funding saw significant growth in Q2’20, setting a new quarterly record. Deals climbed slightly quarter-over-quarter. 

  2. Healthcare & digital health funding in Asia and Europe rebounded from the previous quarter, likely due to reopening efforts amid the pandemic. 

  3. Telehealth deals skyrocketed during the quarter, while funding declined slightly. Q2’20 also saw a record number of exits in the telehealth space. 

  4. The medical device sector reached new heights in both funding and exit volume during the quarter. 

  5. Healthcare AI startups received more than $1B in funding across 84 deals. Though up compared to the previous quarter, financing activity was below the record-setting levels seen in Q3’19. “

Today's News and Commentary

About the public’s health

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders: This blood test could be very useful distinguishing Alzheimer’s from other types of dementia. The research concluded: “Among 1402 participants from 3 selected cohorts, plasma P-tau217 discriminated AD from other neurodegenerative diseases, with significantly higher accuracy than established plasma- and MRI-based biomarkers, and its performance was not significantly different from key CSF- or PET-based measures. Further research is needed to optimize the assay, validate the findings in unselected and diverse populations, and determine its potential role in clinical care.”

Geographic Variation in Overscreening for Colorectal, Cervical, and Breast Cancer Among Older Adults:”In a large, nationally representative, cross-sectional telephone survey with 176 348 participants, more than 45% of older adults in the US reported being screened for colorectal, cervical, or breast cancer after the recommended upper age limit, and overscreening for cervical and breast cancer was more common in metropolitan areas. Life expectancy was not associated with overscreening.”

There May Be 6 Types of COVID-19: Results in a preprint indicate there may be 6 distinct types of COVID-19 clinical illness.

“The six symptom groups in a sequence from least to most severe are: 

  • Headache, loss of smell, muscle pains, cough, sore throat, chest pain, no fever. 

  • Headache, loss of smell, cough, sore throat, hoarseness, fever, loss of appetite. 

  • Headache, loss of smell, loss of appetite, diarrhea, sore throat, chest pain, no cough.

  • Headache, loss of smell, cough, fever, hoarseness, chest pain, fatigue. 

  • Headache, loss of smell, loss of appetite, cough, fever, hoarseness, sore throat, chest pain, fatigue, confusion, muscle pain. 

  • Headache, loss of smell, loss of appetite, cough, fever, hoarseness, sore throat, chest pain, fatigue, confusion, muscle pain, shortness of breath, diarrhea, abdominal pain.”

'Spectacular': Trump praises doctor who dismissed face masks after viral video: I thought this story was from The Onion. Just read it and see if you are amused or appalled.

Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19): “In this cohort study including 100 patients recently recovered from COVID-19 identified from a COVID-19 test center, cardiac magnetic resonance imaging revealed cardiac involvement in 78 patients (78%) and ongoing myocardial inflammation in 60 patients (60%), which was independent of preexisting conditions, severity and overall course of the acute illness, and the time from the original diagnosis…
These findings indicate the need for ongoing investigation of the long-term cardiovascular consequences of COVID-19.”

A desk-based job may lower the risk of cognitive decline: “The research study found that that those with desk jobs — which are typically sedentary roles — have a lower risk of cognitive decline. Moreover, people with lifelong desk-based careers were most likely to be among the study’s top 10% of cognitive performers. 
Conversely, people whose jobs involve manual work have nearly three times the risk of developing poor cognition.”
The researchers warn that: “The relationship between inactivity and cognition is strongly confounded by education, social class and occupation. Physical activity during leisure may be protective for cognition, but work-related physical activity is not protective. A greater understanding of the mechanisms and confounding underlying these paradoxical findings is needed.”

Minnesota Republican county official resigns after posting image comparing mask wearing to Nazi Germany: And we wonder why we are still having a pandemic? “A Minnesota Republican Party county official has resigned after posting an image on Facebook comparing mask mandates to Jews being forced to wear Stars of David in Nazi Germany, the state party said on Tuesday.”

US officials: Russia behind spread of virus disinformation: ”Russian intelligence services are using a trio of English-language websites to spread disinformation about the coronavirus pandemic…
Two Russians who have held senior roles in Moscow’s military intelligence service known as the GRU have been identified as responsible for a disinformation effort meant to reach American and Western audiences, U.S. government officials said…
Between late May and early July, one of the officials said, the websites singled out Tuesday published about 150 articles about the pandemic response, including coverage aimed either at propping up Russia or denigrating the U.S.”

Young people are infecting older family members in shared homes:”…evidence is growing that young people who work outside the home, or who surged into bars and restaurants when states relaxed shutdowns, are infecting their more vulnerable elders, especially family members.”

Preliminary Medicare COVID-19 Data Snapshot: This CMS website provides “current” demographic data about Medicare patients (including Medicare Advantage) with COVID-19 infections. YTD through June 20 there were 550,000 affected Medicare beneficiaries.

XPrize launches $5M COVID-19 testing competition backed by Amazon, Google, Anthem:”XPrize has launched a Rapid Covid Testing competition that will award $5 million to teams that develop faster, cheaper and easier-to-use COVID-19 testing methods at scale.”

Sorrento picks up color-changing COVID-19 saliva test built by Columbia University fertility clinic:”Sorrento Therapeutics has picked up a saliva-based coronavirus test developed by fertility researchers at Columbia University that aims to provide an easy-to-read result in less than 30 minutes.
The entirety of the single-step test, to be dubbed COVI-TRACE, is contained within a small tube—it requires no laboratory equipment and can be used just about anywhere.”

Coronavirus tracker: Do-it-yourself vaccine raises questions; Sanofi's Dupixent 'resilience': This article is a really good update on COVID-19 over the past 10 days. It also mentions that: “A group of scientists in Boston formed a group to create a do-it-yourself experimental vaccine that's administered through the nose, raising legal and ethical questions, MIT Technology Review reports. At least 20 people have given themselves the unproven vaccine.”

About healthcare IT

Pharmacies are also sources of data breaches as evidenced by two stories in today’s news:
CVS Pharmacy loses 21,289 patients' information after vandalism: “CVS Pharmacy reported vandalism at stores in several markets between May 27 and June 8 resulted in the loss of some patient information.
The HHS Breach Portal shows the incident affected 21,289 individuals. The missing information included paper prescriptions, filled prescriptions that had been held in pharmacy waiting bins and vaccine consent forms. Information affected during the vandalism included names, birth dates, addresses, medication names and prescriber information in addition to information about primary care providers. CVS Pharmacy has notified impacted patients.”

Walgreens says 180 stores affected by potential patient data breach: “Walgreens has sent letters to customers telling them that stores nationwide were affected by a potential breach of patient data between May 26 and June 5 and their prescription information may have been compromised. 
The company said that between those dates, thieves stole filled prescriptions and paper records with health information, potentially exposing data including customer names and ages, medication names and dosages, prescription numbers and prescriber names, health plan names and group numbers, and vaccination information, as well as patients' addresses, phone numbers and email addresses.” 

IBM Report: Compromised Employee Accounts Led to Most Expensive Data Breaches Over Past Year: “IBM Security announced today the results of a global study examining the financial impact of data breaches, revealing that these incidents cost companies studied $3.86 million per breach on average, and that compromised employee accounts were the most expensive root cause.” However, healthcare breaches cost the most-$7.13 million.

About health insurance

Anthem earns $2.28B in Q2 profit as payers continue to see strong financial performance amid COVID-19: “Anthem's profits doubled year over year in the second quarter, reaching $2.28 billion, according to the insurer's earnings report released Wednesday morning.
In the second quarter of 2019, Anthem earned $1.14 billion in profits, making it the latest national health plan to report massive financial gains so far this year amid the COVID-19 pandemic.”

The COVID-19 Downturn Triggers Jump in Medicaid Enrollment:”Medicaid enrollment was 72.3 million in April, up from 71.5 million in March and 71 million in February, according to the latest enrollment figures released last week by the Centers for Medicare & Medicaid Services. The increase in March was the first enrollment uptick since March 2017.
About half of the people enrolled in Medicaid are children.”

About pharma

House passes $3.2B FDA budget giving agency power to recall drugs: While only a House bill, if passed by the Senate as well, this measure could be one of the highest impact pharma laws in the decade. The reason is that currently, while the FDA can recall defective products, it cannot require that drugs be taken off the market.

Kodak Shifts Into Drug Production With Help of $765 Million U.S. Loan:”Eastman Kodak Co. has won a $765 million government loan under the Defense Production Act, the first of its kind. The purpose: to help expedite domestic production of drugs that can treat a variety of medical conditions and loosen the U.S. reliance on foreign sources.”

About hospitals and health systems

Systems are now reporting 2nd quarter results. They must repay federal loans and Medicare advances, so these reports must be viewed with caution. Among the reports:

UHS generates $251M in profits thanks to help from COVID-19 relief funds:”The system reported late Monday that its net revenue declined by 4.4% to $2.7 billion in the second quarter compared with $2.85 billion for the same time period in 2019. The earnings reflect other hospital systems that have relied on a massive $175 billion relief fund to help recover from losses sparked by COVID-19.
UHS found that the $251.9 million in profits was slightly above the $238.5 million it generated in the second quarter of 2019.”

HS generates $70M in profits in Q2, got $448M in COVID-19 relief funds:”Community Health Systems generated $70 million in profits in the second quarter of 2019 as government relief funding helped soften the blow of COVID-19…
The second-quarter earnings also represent a significant boost year over year, as CHS suffered a net loss of $167 million in the second quarter of 2019.
CHS generated net operating revenue of $2.5 billion for the quarter.”

Today's News and Commentary

About health insurance

New bill seeks to boost participation in advanced payment models, ACOs via several reforms:”The Value in Health Care Act introduced on July 24 proposes several changes to Medicare’s alternative payment models. It would boost payments for not only ACOs but also extend bonus payments to clinicians working in advanced APMs.”

About healthcare quality

2020-21 Best Hospitals Honor Roll and Medical Specialties Rankings: Annual US News rankings.
Mayo is overall #1.

About pharma

Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike: Researchers “report the isolation of 61 SARS-CoV-2-neutralizing monoclonal antibodies from 5 infected patients hospitalized with severe disease.” The implication is that vaccines and treatments may need to have multiple components to successfully prevent or fight SARS-CoV-2.

Identification of an Anti-diabetic, Orally Available Small Molecule that Regulates TXNIP Expression and Glucagon Action: Researchers found the small molecule SRI-37330 inhibits expression of the gene TXNIP in mouse and human pancreatic islet cells that are responsible for glucose regulation. Oral SRI-37330 decreases glucagon secretion (which increases blood sugar), blocks hepatic glucose output and reverses obesity. This potential drug represent s a new mechanism for diabetes treatment.

Disrupting the platelet internal membrane via PI3KC2α inhibition impairs thrombosis independently of canonical platelet activation: Antiplatelet therapy to prevent strokes and heart attacks impairs platelets’ ability to form clots and can lead to bleeding disorders. Researchers found a more targeted mechanism that prevents clotting related only to impaired flow. If a workable drug can be found that achieves this effect it would be a safer alternative to current therapies.

Generic drug trade group loses bid to block California pay-to-delay law:”A federal appeals court denied a bid by generic drug trade group Association for Accessible Medicines to block a California law banning pay-to-delay deals between drugmakers….
Pay-to-delay deals happen when a brand-name drugmaker pays a generic drugmaker to delay launching a generic version of a drug so the brand-name drugmaker can continue selling it without competition for a longer period of time. 
The Federal Trade Commission has said such deals cost U.S. consumers about $3.5 billion annually. 
California became the first state to outlaw such deals in October 2019.”

Drugmakers refuse to attend White House meeting after Trump issues executive orders on costs: “A White House meeting with top pharmaceutical executives that President Donald Trump promised for Tuesday is off, five industry sources familiar with discussions told POLITICO. Three said the drug-pricing discussion was canceled because the major drug lobbies, reeling from Friday’s cluster of executive orders on the topic, refused to send any members.”

President Trump announces $265 million award to Fujifilm for coronavirus vaccine manufacturing: “The Department of Health and Human Services awarded the contract, which reserves manufacturing capacity  through the end of 2021, to the Fujifilm Texas A&M Innovation Center in College Station, Texas.”

AstraZeneca, Daiichi Sankyo in $6B oncology deal: “AstraZeneca PLC said Monday that it has entered into an oncology collaboration with Daiichi Sankyo Co. worth up to $6 billion that it said could redefine treatment standards in lung, breast and multiple other cancers.
The British pharmaceutical giant said it and Daiichi Sankyo will jointly develop and commercialize a new antibody drug conjugate, DS-1062, world-wide, except in Japan. The drug is currently in development, AstraZeneca said.”

Indivior to pay $600 million to settle U.S. opioid treatment marketing claims:”The indictment alleged Indivior deceived doctors and healthcare benefit programs into believing the film version of Suboxone, which has an opioid component, was safer and less susceptible to abuse than similar drugs…
The company is also settling related civil lawsuits the Justice Department joined in 2018… to resolve claims by the Federal Trade Commission that it impeded competition from generic equivalents of Suboxone.”

Pfizer, BioNTech start their COVID-19 vax phase 3, squaring off with Moderna:”Moderna announced early Monday that, alongside a near half-billion extra in Biomedical Advanced Research and Development Authority dollars, it has started a boosted 30,000-patient phase 3 for its vaccine; not to be left out, Pfizer and BioNTech announced after-hours that they too were starting a late-stage attempt.”

About the public’s health

Postmarketing Safety of Vaccines Approved by the U.S. Food and Drug Administration: Not that this study will change the opinions of anti-vaxxers, but researchers found that: “Over a 20-year period, vaccines were found to be remarkably safe. A large proportion of safety issues were identified through existing postmarketing surveillance programs and were of limited clinical significance. These findings confirm the robustness of the vaccine approval system and postmarketing surveillance.”

Effectiveness of surgical masks against influenza bioaerosols: Masks have been recommended to prevent the wearer from spreading a contagion. In this study, researchers developed a model to gauge the effectiveness of protection for the wearer. They found: “Live influenza virus was measurable from the air behind all surgical masks tested. The data indicate that a surgical mask will reduce exposure to aerosolised infectious influenza virus; reductions ranged from 1.1- to 55-fold (average 6-fold), depending on the design of the mask.”

Florida judge upholds coronavirus ordinance requiring masks:”A Florida judge on Monday upheld a county’s coronavirus ordinance that requires masks be worn in public places like stores, saying government officials have the authority to protect their residents from the spread of infectious diseases.”

FDA expands list of potentially deadly hand sanitizers:”The US Food and Drug Administration has expanded its list of potentially deadly hand sanitizer products, warning a Mexican-based company about selling products that contain methanol, a dangerous form of alcohol that can poison people through their skin.”

Today's News and Commentary

About health insurance

AHA, AAMC press appeals court for rehearing on site-neutral payments case: “The American Hospital Association (AHA) and Association of American Medical Colleges (AAMC) announced Friday they are seeking a rehearing on the ruling earlier this month from the U.S. Court of Appeals for the District of Columbia. The ruling upheld the Department of Health and Human Services’ (HHS) authority to install Medicare payment cuts to off-campus hospital clinics to bring them to the same payment level as physician offices.”

About pharma

Trump signs orders to lower prescription drug prices: As announced in Friday’s blog, Trump signed executive orders aimed at lowering drug prices.
”One order would allow for the legal importation of cheaper prescription drugs from countries like Canada, while another would require discounts from drug companies now captured by middlemen to be passed on to patients, Trump said. 
Another measure seeks to lower insulin costs while a fourth, which may not be implemented if talks with drug companies are successful, would require Medicare to purchase drugs at the same price that other countries pay, Trump said.” Pharma companies have until August 25 to come up with a plan.
For White House texts of the orders, see: Executive Order on Access to Affordable Life-saving Medications and Remarks by President Trump at Signing of Executive Orders on Lowering Drug Prices.

The top 20 drugs by global sales in 2019: Leading the group is Humira's $19.74 billion in sales.

1 in 3 hospital pharmacies face shortage of remdesivir, survey funds: “A new report from the American Society of Health-System Pharmacists polls 112 respondents on a number of concerns related to the pandemic. While some expressed concern about supply of remdesivir, supplies of intensive care medications are improving, the survey found.”

About the public’s health

FDA authorizes first COVID-19 test for screening people without symptoms: “Previously, the agency’s testing green lights were reserved for people showing early signs of an infection, such as a fever, as well as high-risk individuals and front-line healthcare workers…
The new regulatory expansion goes to LabCorp’s coronavirus diagnostic test…. The agency also endorsed its use for batch testing, which allows up to five samples to be combined and analyzed at once to stretch testing supplies and speed up screening efforts.”

Coronavirus Vaccine Put To Final Test In Thousands Of Volunteers: “The world’s biggest COVID-19 vaccine study got underway Monday with the first of 30,000 planned volunteers helping to test shots created by the U.S. government —… developed by the National Institutes of Health and Moderna Inc….”

Flu, Pneumonia Vaccinations Tied to Lower Risk of Alzheimer's Dementia: Another reason to get these vaccinations. The research found:

  • “At least one flu vaccination was associated with a 17% reduction in Alzheimer’s incidence. More frequent flu vaccination was associated with another 13% reduction in Alzheimer’s incidence.

  • Vaccination against pneumonia between ages 65 and 75 reduced Alzheimer’s risk by up to 40% depending on individual genes. 

  • Individuals with dementia have a higher risk of dying (6-fold) after infections than those without dementia (3-fold).”

About healthcare IT

10 concerning trends in health IT: A nice summary of some current trends, including problems.

Today's News and Commentary

Sunday, July 26, 2020, marks the 30th anniversary of the signing of the Americans with Disabilities Act. 

About the public’s health

Renewal of Determination That A Public Health Emergency Exists: Starting tomorrow, HHS Secretary Azar will extend the COVID-19 public health emergency status for another 90 days.

U.S. coronavirus deaths top 1,100 for a third day in a row: Total cases have now reached 4 million.

Impact of self-imposed prevention measures and short-term government-imposed social distancing on mitigating and delaying a COVID-19 epidemic: A modelling study: “Based on our results, we conclude that handwashing, mask-wearing, and social distancing adopted by disease-aware individuals can delay the epidemic peak, flatten the epidemic curve, and reduce the attack rate. We show that the rate at which disease awareness spreads has a strong impact on how self-imposed measures affect the epidemic… For all measures, a large epidemic can be prevented when the efficacy exceeds 50%. Moreover, the effect of combinations of self-imposed measures is additive. In practical terms, it means that SARS-CoV-2 will not cause a large outbreak in a country where 90% of the population adopts handwashing and social distancing that are 25% efficacious (i.e., reduce susceptibility and contact rate by 25%, respectively)…
The potential second wave could be prevented altogether if the coverage of a self-imposed measure in the population and its efficacy are sufficiently high (e.g., 90% and 50%, respectively). Our sensitivity analyses showed that lower or higher efficacies can be required to prevent a large epidemic for countries with smaller or larger basic reproduction numbers…”

Estimated County-Level Prevalence of Selected Underlying Medical Conditions Associated with Increased Risk for Severe COVID-19 Illness — United States, 2018: This report from the CDC was published today and has a shocking revelation: “The median model-based estimate of the prevalence of any of five underlying medical conditions associated with increased risk for severe COVID-19–associated illness among U.S. adults was 47.2% among 3,142 U.S. counties. The estimated number of persons with these conditions followed population distributions, but prevalence was higher in more rural counties.” The five conditions are chronic obstructive pulmonary disease, cardiovascular disease, diabetes, chronic kidney disease, and obesity.

Why COVID-19 is killing U.S. diabetes patients at alarming rates: “At the microscopic level, high glucose and lipid counts in diabetes patients can trigger a ‘cytokine storm,’ when the immune system overreacts, attacking the body. Damaged endothelial cells, which provide a protective lining in blood vessels, can lead to inflammation as white blood cells rush to attack the virus and may cause lethal clots to form, emerging research suggests.”

‘It’s Like Groundhog Day’: Coronavirus Testing Labs Again Lack Key Supplies:”Pipette tips aren’t the only laboratory items in short supply. Dwindling stocks of machines, containers and chemicals needed to extract or amplify the coronavirus’s genetic material have clogged almost every point along the testing workflow.”

Neonatal management and outcomes during the COVID-19 pandemic: an observation cohort study:”Of 1481 deliveries, 116 (8%) mothers tested positive for SARS-CoV-2; 120 neonates were identified. All neonates were tested at 24 h of life and none were positive for SARS-CoV-2…. Our data suggest that perinatal transmission of COVID-19 is unlikely to occur if correct hygiene precautions are undertaken, and that allowing neonates to room in with their mothers and direct breastfeeding are safe procedures when paired with effective parental education of infant protective strategies.”

Coffee, Caffeine, and Health: Excellent article from the NEJM on this topic. (Can access by signing up for 3 free articles/month). Among the benefits: “coffee consumption was associated with a reduced risk of cardiovascular diseases, with the lowest risk for 3 to 5 cups per day. An inverse association has been observed between coffee consumption and coronary artery disease, stroke, and death from cardiovascular causes.” Filtered coffee is best, then espresso, then unfiltered. The article also discussed tea and “energy drinks.”

Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials: A number of interventions are discussed with their recommendation confidence based on the scientific literature. “With credible though inconclusive evidence, the suggestions targeted 10 risk factors including diabetes, hyperhomocysteinaemia, poor BMI management, reduced education, hypertension in midlife, orthostatic hypotension, head trauma, less cognitive activity, stress and depression.”

China offers $1 billion loan to Latin America and the Caribbean for access to its Covid-19 vaccine:”The virtual meeting on Wednesday was led by Mexico's Foreign Affairs Minister, Marcelo Ebrard, and [Chinese Foreign Minister] Wang Yi. Their counterparts from Argentina, Barbados, Chile, Colombia, Costa Rica, Cuba, the Dominican Republic, Ecuador, Panama, Peru, Trinidad and Tobago and Uruguay also joined.”

About hospitals and health systems

General and Targeted Distribution Post-Payment Notice of Reporting Requirements Relief Fund (PRF) recipients that received one or more payments exceeding $10,000 in the aggregate from the PRF must report by Feb. 15, 2021 how they spent the relief grants. The reporting will be available strait October 1, 2020. Detailed instructions regarding these reports will be released by August 17, 2020.

About pharma

Trump likely to sign executive orders on drug pricing Friday:”The exact details of the orders remain unclear, but sources say one order is likely to include a version of a proposal to reduce some U.S. drug prices by tying them to the lower prices paid in other countries. 
An idea that had been in the mix earlier in the week, to eliminate the rebates drugmakers pay to negotiators known as pharmacy benefit managers (PBMs), is now unlikely to be included, sources say.”

U.S. clears way for drugmakers to share COVID antibody capacity: “The U.S. Department of Justice on Thursday said it will not stand in the way of efforts by companies, including Eli Lilly and Co and Amgen Inc, to share information to help scale up capacity to manufacture antibody treatments for COVID-19, the disease caused by the new coronavirus….
The DOJ did not include Regeneron Pharmaceuticals Inc, which expects to have definitive trial results for its dual-antibody treatment by late summer or early fall. The Department of Health and Human Services in June awarded Regeneron a $450 million contract and the company has cleared the way for U.S. manufacturing of its antibody cocktail by moving production of its other products to a plant in Ireland.”

AstraZeneca confirms Russia vaccine deal days after COVID-19 hacking accusations surface:”Last week, Western intelligence officials pegged Russian hackers with an attempt to rip off leading research for a COVID-19 vaccine, linking the would-be thieves with the country's intelligence services.
Russia itself denies involvement in any of those attacks—and with a new licensing deal for AstraZeneca's COVID-19 shot, the country says it doesn't need the secrets anyway.
Russian drugmaker R-Pharm has signed a licensing deal with Britain's AstraZeneca to produce and distribute doses of its University of Oxford-partnered adenovirus-based COVID-19 shot, AZD1222.”

Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19: Do we really need another study showing lack of effectiveness? Here is one anyway (from Brazil): “Among patients hospitalized with mild-to-moderate Covid-19, the use of hydroxychloroquine, alone or with azithromycin, did not improve clinical status at 15 days as compared with standard care.”

U.S. sets global benchmark for COVID-19 vaccine price at around the cost of a flu shot:”The U.S. government has set a benchmark for COVID-19 vaccine pricing in a $2 billion deal announced on Wednesday with Pfizer Inc and German biotech BioNTech SE that will likely pressure other manufacturers to set similar prices, industry analysts told Reuters.
The deal, which is contingent on an approvable product, secures enough vaccine to inoculate 50 million Americans for about $40 a person, or about the cost of annual flu shots, and is the first to provide a direct window into likely pricing of successful COVID-19 vaccines.”

Biotech Startups Cash In With IPOs in First Half: “Drug startups capitalized on soaring interest in biotechnology to stage 26 initial public offerings globally in the first half of this year, putting 2020 on pace to be one of the strongest ever for new stock offerings in the sector.”

FDA Poses March Deadline for Reporting Unapproved Drug Use: “Drug companies would have until the end of March to tell the FDA which unapproved drugs they offered sick patients through the federal Right to Try law and whether they caused serious side effects under a proposed rule the agency released Thursday.
The rule is aimed to give the Food and Drug Administration a clearer picture of how patients are using experimental drugs through the law’s annual reporting requirements. It would also help provide the first comprehensive look at how effective the law has been at getting terminally ill patients access to the latest medications.”

Moderna loses US patent challenge that could affect COVID-19 vaccine:”Shares in Moderna fell as much as 10% Thursday after the company failed in an attempt to invalidate a US patent on vaccine technology held by Arbutus Biopharma. SVB Leerink analyst Mani Foroohar suggested the decision by an administrative court run by the US Patent and Trademark Office opens the door to debate around Moderna's entire pipeline, with the near-term concern being its experimental coronavirus vaccine mRNA-1273, which is due to enter Phase III testing later this month.”

About health insurance

Aetna aims to offer alternative to high-deductible plans in 2 new benefit designs:”The new designs, called Upfront Advantage and Flexible Five, offer members coverage for some preventive services before they meet their deductibles. In Upfront Advantage, members will have access to services worth up to $500 for an individual and $1,000 for a family for free before their deductible is met. 
In Flexible Five, members will instead be offered five coupons per person for these services; a family of four, for example, would receive 20 coupons that can be applied to services such as primary care visits, behavioral health visits, urgent care, lab tests or x-rays conducted during those visits and generic drugs.”

Nearly 11M paid premiums for ACA exchanges at beginning of 2020, a slight increase:”The Centers for Medicare & Medicaid Services (CMS) reported Thursday that 10.7 million ACA customers paid their premiums as of March 15, a slight increase from the 10.6 million who paid through February 2019. The data include both state and federally run insurance exchanges.”

Humana plans to send 1 million home screening kits to its members: “Humana said it will send 1 million test kits to its members to allow them to access preventive screenings at home. The insurer said it would send its Medicare Advantage members at-home colorectal cancer screenings and diabetic management test kits. Humana’s Medicaid members will also have access to the diabetic management test kits.” One advantage to the insurer is maintenance of quality scores for screening, which affects payment levels.

Association Between Switching to a High-Deductible Health Plan and Major Cardiovascular Outcomes: In a finding consistent with other studies on high deductibles and serious illness, the authors found that: “Mandated enrollment in high-deductible health plans with typical value-based features was not associated with increased risk of major adverse cardiovascular events.”

About healthcare IT

In Push for Better Cybersecurity, U.S. Energy Department Outlines a National Quantum Internet: While not strictly applicable to healthcare, this development can have profound benefits in the sector. For example, the public’s confidence in enhanced security would help allay fears of a unique patient identifier.
“A group led by the U.S. Department of Energy and the University of Chicago plans to develop a nationwide quantum internet that could be functional in about a decade and with the potential to securely transmit sensitive information related to national security and financial services…
The project will be funded by a portion of the $1.275 billion budget allocated as part of President Trump’s National Quantum Initiative, an effort to accelerate research and development in quantum information science, an area of study that includes quantum-based communication and quantum computing.”

Clinical, Legal, and Ethical Aspects of Artificial Intelligence–Assisted Conversational Agents in Health Care: With the rapid growth in telemedicine, this article is a great summary of the issues mentioned in the title. By way of definition: “Conversational agents (CAs) are artificial intelligence (AI) programs that engage in a dialogue with users by interpreting their questions or concerns and replying to them in a text message, image, or voice format. Conversational agents typically imitate human conversation by applying natural language processing and machine learning and stand in contrast to text-based engagement platforms that accept discretely formatted human inputs and reply with preset messages.”

 Abbott receives FDA approval for neurostimulator-controlling iPhone app, for personalizing therapies for pain, Parkinson's disease: “The FDA approved a new smartphone app from Abbott allowing people to personalize their own neuromodulation therapies, including regimens for chronic pain and movement disorders such as Parkinson’s disease.
Compatible with Apple products, the devicemaker’s NeuroSphere Digital Care platform and its newly approved patient controller app are also designed to encourage more virtual connections with healthcare providers, and allow interactions to take place remotely in the face of the COVID-19 pandemic.”

Cerner inks partnership with point-of-care decision-making platform: “Cerner announced July 23 a new agreement to deploy Holon Solutions' point-of-care platform that can extract relevant patient information from Cerner's population health platform and deliver it into the clinician's EHR workflow.”

Today's News and Commentary

About the public’s health

Feasibility of Separate Rooms for Home Isolation and Quarantine for COVID-19 in the United States: “More than 1 in 5 U.S. homes, housing about one quarter of all Americans, lack sufficient space and plumbing facilities to comply with recommendations to isolate or quarantine to limit household spread of COVID-19. This proportion is particularly high among homes occupied by minority and poor individuals and among apartments…”

Poll: 3 In 4 Americans Support Mask Requirements: According to a NORC-AP poll: “Three out of four Americans, including a majority of Republicans, favor requiring people to wear face coverings while outside their homes, a new poll finds, reflecting fresh alarm over spiking coronavirus cases and a growing embrace of government advice intended to safeguard public health.”

COVID-19 screening strategies that permit the safe re-opening of college campuses: Note, this article has not yet been peer reviewed. This simulation was a cost-effectiveness analysis of “campus screening using tests of varying frequency (daily-weekly), sensitivity (70%-99%), specificity (98%-99.7%), and cost ($10-$50/test)…Across all scenarios, test frequency exerts more influence on outcomes than test sensitivity. Cost-effectiveness analysis selects screening every {2, 1, 7} days with a 70% sensitive test as the preferred strategy for Rt = {2.5, 3.5, 1.5}, implying a screening cost of {$470, $920, $120} per student per semester. Conclusions & Relevance: Rapid, inexpensive and frequently conducted screening (even if only 70% sensitive) would be cost-effective and produce a modest number of COVID-19 infections. While the optimal screening frequency hinges on the success of behavioral interventions to reduce the base severity of transmission (Rt), this could permit the safe return of student to campus.”

Over half of U.S. companies plan virus contact tracing for employees: survey: In this study by Mercer of more than 300 companies, “54% are planning to implement a contact tracing program or had already started one…
Among those who responded, the survey found that 42% of companies said they are using existing employees to do contact tracing and 9% are training employees now. In addition, about 4% said they will be hiring more staff and/or a vendor for their contact-tracing efforts, and about 3% plan to use a smart phone app or wearable device to track employee contacts.”

About health insurance

Another Problem on the Health Horizon: Medicare Is Running Out of Money: Medicare Trustees recently said the hospital trust fund will go bankrupt in 2026 (unchanged from previous estimates). Dr. David Shulkin (former undersecretary for health at the Department of Veterans Affairs and now now a senior fellow at the Leonard Davis Institute of Health Economics at the University of Pennsylvania)  did his own projections. “Given even a conservative estimate of how many workers and businesses would not be contributing payroll taxes that finance Part A spending, he said, the trust fund could become insolvent as early as 2022 or 2023.”

About pharma

Roche suffers double whammy as biosimilars, COVID-19 joined hands in weak quarter: The three drugs are Avastin, Rituxan and Herceptin. The first half of year impact is $2.3 billion.

About healthcare IT

Lessons from year one of Blue Shield of California's Wellvolution program: The article provides encouragement for other insures who want to implement similar programs.
“Over the past year, Blue Shield of California has grown its Wellvolution digital and community health network into the largest in the nation.
The platform includes close to 60 digital apps and covers services at 30,000 locations. About 26,000 Blue Shield members are currently enrolled in Wellvolution, the insurer said. Through the platform, members are matched with customized programs and digital coaching for a number of health conditions, including diabetes, hypertension, obesity and behavioral health needs.”

Today's News and Commentary

About the public’s health

Deciding Who Should Be First in Line for the Coronavirus Vaccine: Here is the text of my NY Times letter published today:

“The debate in the article centers on who should get priority to receive the coronavirus vaccine when it first comes out. Another consideration is where it should first be deployed. Politics may dictate that it go to states that currently have the highest incidence, i.e., many red states. However, many places in those states are not prudently practicing quarantine, masking and social distancing.

Would it be fair to those states with sensible policies that they have to wait for the vaccine?”

The comment is meant to spur debate between two rationales for allocating the vaccine.
Recall that the vaccine is targeted to be 50-75% effective. Now that evidence points to the need for two injections, it may prove to be even less effective. This concern raises the further question of the overall effectiveness in a setting without social distancing and mask wearing. In other words, we need to ask: Would the vaccine be “wasted” in that setting? Would the vaccine be more useful in accomplishing the goal of zero infections if it were part of a portfolio of measures? To answer some of these questions, it is nice to see the following announcement: National Academies Launch Study on Equitable Allocation of a COVID-19 Vaccine – First Meeting July 24: “As part of the study, the committee will consider what criteria should be used to set priorities for equitable distribution among groups of potential vaccine recipients, taking into account factors such as population health disparities; individuals at higher risk because of health status, occupation, or living conditions; and geographic distribution of active virus spread.  In addition, the committee will consider how communities of color can be assured access to COVID-19 vaccines in the U.S. and recommend strategies to mitigate vaccine hesitancy among the American public.”

HHS Coronavirus Data Hub:This dashboard replaces the CDC's National Healthcare Safety Network (NHSN) for reporting COVID-19 related data, such as intensive care unit capacity, ventilator use, personal protective equipment (PPE) levels, and staffing shortages.

Trump shifts rhetoric as he urges mask-wearing, warns of worsening pandemic: “President Donald Trump, in a shift in rhetoric and tone, encouraged Americans on Tuesday to wear masks if they cannot maintain social distance and warned that the coronavirus pandemic would get worse before it got better.”

Former CDC chief: Most states fail to report data key to controlling the coronavirus pandemic: “Not a single state reports on the turnaround time of diagnostic covid-19 tests…Six months after the first coronavirus case  appeared in the United States, most states are failing to report critical information needed to track and control the resurgence of covid-19, the disease caused by the virus, according to an analysis released Tuesday” by former Centers for Disease Control and Prevention director Tom Frieden. “His team and other public health leaders are recommending that states and counties report 15 indicators they say are essential for an effective response.”

How long will immunity last after COVID-19 infection?While the data is not yet clear, here are a couple articles that try to answer the question:

Sweden Says Covid Immunity Can Last 6 Months After Infection: “Sweden’s top health authority says people who have had the novel coronavirus are likely to be immune for at least six months after being infected, whether they’ve developed antibodies or not…’We don’t see cases of people falling ill twice from Covid-19,’ state epidemiologist Anders Tegnell said during a press conference in Stockholm. ‘Hence, our assessment is that if you do get Covid-19 you are immune, even if you don’t develop antibodies.’”

Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19: “The protective role of antibodies against SARS-CoV-2 is unknown… Given that early antibody decay after acute viral antigenic exposure is approximately exponential, we found antibody loss that was quicker than that reported for SARS-CoV-1… Our findings raise concern that humoral immunity against SARS-CoV-2 may not be long lasting in persons with mild illness, who compose the majority of persons with Covid-19. It is difficult to extrapolate beyond our observation period of approximately 90 days because it is likely that the decay will decelerate. Still, the results call for caution regarding antibody-based ‘immunity passports,’ herd immunity, and perhaps vaccine durability, especially in light of short-lived immunity against common human coronaviruses. Further studies will be needed to define a quantitative protection threshold and rate of decline of antiviral antibodies beyond 90 days.”

Genes May Influence COVID-19 Risk, New Studies Hint: A nice summary of this issue from Scientific American. “Combing through the genome, researchers have tied COVID-19 severity and susceptibility to some genes associated with the immune system’s response, as well as a protein that allows the disease-causing SARS-CoV-2 coronavirus into our cells. They have also turned up links between risk and a person’s blood type—A, B, AB or O. The findings are not cut-and-dried, however. “

Polio vaccination campaigns restart after modelers warn about risk of ‘explosive’ outbreaks:”In a sad knock-on effect of the COVID-19 pandemic, the Global Polio Eradication Initiative (GPEI) abruptly halted all mass vaccination campaigns in March, worried they could inadvertently spread the novel coronavirus. The move further imperiled the troubled 3-decade drive to wipe out polio.
But now, armed with new data and perspective, GPEI and the countries it supports are resuming vaccination campaigns.”

Poor diets threaten US national security — and it's serious: “Diet-related illnesses are a growing burden on the United States economy, worsening health disparities and impacting national security, according to a white paper published Monday in the American Journal of Clinical Nutrition.
Poor nutrition is the leading cause of illnesses in the US, with unhealthy diets killing more than half a million people each year, a group of experts who have formed the Federal Nutrition Research Advisory Group wrote in the paper.
About 46% of adults in the country have an overall poor-quality diet, and this number goes up to 56% for children…
The paper's authors called for the expansion of federal investment in nutrition science by creating a new Office of the National Director of Food and Nutrition or a new US Task Force on Federal Nutrition Research, with the goal of improving coordination within the agencies that budget for research in this topic.”

Physicians’ progress toward ending the nation’s drug overdose and death epidemic: A couple important takeaways from the report:
—”37.1% decrease in opioid prescriptions from 244.5M in 2014 to 153.7M in 2019…
—Despite these efforts, illicitly manufactured fentanyl, fentanyl analogues and stimulants (e.g. methamphet- amine, cocaine) are now killing more Americans than ever. The use of these illicit drugs has surged and their overdose rate increased by 10.1% and 10.8%, respectively.”

US signs contract with Pfizer for COVID-19 vaccine doses: “The Trump administration will pay Pfizer nearly $2 billion for a December delivery of 100 million doses of a COVID-19 vaccine the pharmaceutical company is developing, Health and Human Services Secretary Alex Azar announced Wednesday. 
The U.S. could buy another 500 million doses under the agreement…”

About health insurance

Are Employers Satisfied that Their Health Plans Drive Quality, Safety, and Value?:This report from the Leapfrog Group polled “174 employers representing an estimated 4 million insured lives… Respondents cited their experience with health plans including Aetna, Cigna, UnitedHealthcare, as well as a range of BlueCross and BlueShield (BCBS) plans, including Anthem and over a dozen state BCBS plans.” The results were divided over 4 criteria:

  1. Responsiveness of the health plan to employer concerns;

  2. Transparency in helping employers and employees choose the best providers;

  3. Payment reform initiatives that incentivize excellence in the market; and

  4. Value strategies driven by health plans.

You should read the whole study but here are some pertinent facts:
”The final question asked of the employers was to grade their health plan, from A to F, on their ability to direct their employees to high-quality health care. Overall, employer respondents gave their plans a C-plus (2.57 GPA). The larger employers were tougher on the health plans than the mid-size to small employers….

Among the plans reported in the survey, Cigna was a clear leader in the movement for value. Employers gave UnitedHealthcare the lowest ratings, with the most room for improvement in driving for value, reducing costs and improving quality. Aetna led among plans for putting a focus on quality.”

California Blues earned $1B ACA risk adjustment payment last year. Here's how other insurers fared:”Risk adjustment transfers totaled $10.8 billion in 2019, with some insurers on the ACA's exchanges earning substantial payouts, according to new data from the Trump administration.
The Centers for Medicare & Medicaid Services released (PDF) its annual look at the Affordable Care Act's risk adjustment program, and said that 561 insurers participated in 2019. The $10.8 billion was split evenly between payments made to insurers and payments to CMS to maintain budget neutrality.
The individual market accounted for the largest share of transfers, or about $7.98 billion.”

Insurers worry drug companies could game changes to Medicaid rebate program in new rule:”Several insurer groups commented on the proposed rule that the Centers for Medicare & Medicaid Services (CMS) released last month to get states and drugmakers to create more value-based payment arrangements.
If finalized, the rule would relax some of the requirements for the average manufacturer price and best price that manufacturers must provide for Medicaid. Under the new rule, a manufacturer could report multiple best prices for a therapy under the Medicaid Drug Rebate Program, but any best price has to be tied to a value-based purchasing agreement.
A manufacturer could also use a ‘bundled sales’ approach that allows a manufacturer to calculate a weighted average for discounts across a drug class. If there is a performance-based failure for the drug, it is allocated proportionally for all products sold in the bundle.
But payers were concerned manufacturers could game the new multiple “best price” provision. For instance, the manufacturer could offer a variety of rebates based on a patient’s response to a drug, but questions remain on how states will track those outcomes.”

About pharma

How COVID-19 could be crippled by an age-old blood thinner:Scientists at Rensselaer Polytechnic Institute “discovered that SARS-CoV-2 binds tightly to heparin, making the drug a potential ‘decoy’ that could serve as a way to neutralize the virus before it can infect healthy cells. They reported the finding (PDF) in the journal Antiviral Research.”

Novartis' second-quarter sales, profit fall as COVID-19 stockpiling reverses: Many healthcare institutions stockpiled medications in the first quarter. Now pharma performance results will show the effect of reduced 2nd quarter purchases.

10 most valuable R&D projects in the pharmaceutical industry pipeline: The headline is self explanatory.

COVID-19: EMA sets up infrastructure for real-world monitoring of treatments and vaccines:”EMA has now set up an infrastructure to support the monitoring of the efficacy and safety of COVID-19 treatments and vaccines when used in day-to-day clinical practice. This is underpinned by three contracts for observational research that EMA has signed with academic and private partners over recent months, to be ready to effectively monitor vaccines in the real world as soon as they are authorised, and support the safe and effective use of COVID-19 vaccines and medicines.
The latest contract was finalised in mid-July with Utrecht University and the University Medical Center Utrecht as coordinators of the CONSIGN project (‘COVID-19 infectiOn aNd medicineS In preGNancy’).”
Do we have a similar entity in this country?

Today's News and Commentary

About the public’s health

How long should you isolate if you test positive for the coronavirus? At least 10 days after symptom onset:”The CDC had previously recommended people who test positive isolate until they had two negative swabs for the coronavirus — but that turned out to be impractical given the shortage of tests. It now advises most people with active cases of covid-19, the illness caused by the coronavirus, to isolate for 10 days after symptoms begin and 24 hours after their fever has broken. After that, they are free to leave isolation.”

President Trump defends response to COVID crisis in exclusive interview with Chris Wallace: This article is a transcript of the “Fox News Sunday," July 19, 2020 interview with the President. Read it in its entirety.

Trump Says He ‘Aced’ a Cognitive Test. What Does That Really Mean?: The article is not really a political comment but a good summary of the value of cognitive testing.

Erythrocyte omega-3 index, ambient fine particle exposure and brain aging: As we age, brain white matter shrinks. Air pollution makes it worse. In this study of women ages 65-80, consumption of omega-3s (largely from fish) mitigated these changes.

Blue states sue HHS over controversial transgender coverage rule:”A collection of 23 states is suing the Trump administration over a rule the states say eliminated healthcare protections for transgender Americans.
The states, which are led by California, Massachusetts and New York, argue in the lawsuit filed Monday that the rule finalized last monthviolates the Affordable Care Act (ACA)—which prohibits discrimination in federal healthcare such as Medicare, Medicaid and the exchanges—and the equal protection guarantee within the U.S. Constitution.”

We'll need enormous numbers of Americans to test COVID-19 vaccines; a 'very encouraging' 138,600 have signed up: The headline speaks for itself.

Social determinants of health amplify stroke risk in adults younger than 75 years:”Among adults younger than 75 years, those with multiple social determinants of health were at more than a 2.5-fold greater risk for stroke than those without any, according to new data from the REGARDS study. 
Determinants most strongly associated with stroke were race, education, income, ZIP code poverty, health insurance, social isolation and residence in one of the 10 lowest-ranked states for public health infrastructure.”

Race, Postoperative Complications, and Death in Apparently Healthy Children: “Among 172 549 apparently healthy children, the incidence of 30-day mortality, postoperative complications, and serious adverse events were 0.02%, 13.9%, and 5.7%, respectively. Compared with their white peers, AA [African American]children had 3.43 times the odds of dying within 30 days after surgery (odds ratio: 3.43; 95% CI: 1.73–6.79). Compared with being white, AA had 18% relative greater odds of developing postoperative complications (odds ratio: 1.18; 95% CI: 1.13–1.23) and 7% relative higher odds of developing serious adverse events (odds ratio: 1.07; 95% CI: 1.01–1.14)…Mechanisms underlying the established racial differences in postoperative outcomes may not be fully explained by the racial variation in preoperative comorbidity.”

Double-Shot Covid Vaccines Multiply Immunization Challenges: “When it comes to protecting the world from the coronavirus, two doses of a vaccine may be better than one. But doubling the number of jabs each person needs could complicate efforts to immunize billions of people.
The latest results from front-runners in the sprint to come up with a vaccine, including the University of Oxford-AstraZeneca Plc partnership and Modern Inc.., highlight that prospect. Both efforts are conducting final-stage testing with two doses.”

Testimony of Macaya Douoguih, M.D., M.P.H. Head of Clinical Development and Medical Affairs, Janssen Vaccines and Prevention Johnson & Johnson: Submitted to the Oversight & Investigation Subcommittee of the U.S. House of Representatives Energy & Commerce Committee: In today’s prepared statement, J&J gave an update on its vaccine progress and made a promise that: “Johnson & Johnson is committed to bringing an affordable COVID-19 vaccine to the public on a not-for-profit basis for emergency pandemic use… We are committed to one price globally, regardless of country or income tier. The not-for-profit price will be for the emergency pandemic period.
Our not-for-profit framework is consistent with established vaccine costing methodologies. Our price will be determined based on one cost structure, with all appropriate costs included. We are pursuing external validation of our not-for-profit calculation approach and external audit / certification of not-for-profit price.”

Two Chinese Hackers Working with the Ministry of State Security Charged with Global Computer Intrusion Campaign Targeting Intellectual Property and Confidential Business Information, Including COVID-19 Research: This announcement came today from the Department of Justice. It is on the heels of the Russian hack last week.

About health insurance

Administration Eases Rules to Give Laid-Off Workers More Time to Sign Up for COBRA:”Under the federal law known as COBRA, people who lose their job-based coverage because of a layoff or a reduction in their hours generally have 60 days to decide whether to continue their health insurance. But under the new rule, that clock doesn’t start ticking until the end of the COVID-19 “outbreak period,” which started March 1 and continues for 60 days after the COVID-19 national emergency ends. That end date hasn’t been determined yet.
By extending the time frame to sign up for COBRA coverage, people have at least 120 days to decide whether they want to elect COBRA, and possibly longer depending on when they lost their jobs.”

About hospitals and health systems

The Effect of COVID-19 on Hospital Financial Health: KaufmanHall prepared this report for the AHA. —Before COVID-19 the median hospital margin was 3.5%
—Funding from the CARES Act (distributed April, May and June) is mitigating the negative financial “impact to a certain degree. Median margins are forecast to drop to –3% in the second quarter of 2020; however, those margins would have been –15% without CARES Act funding.”
—”In the most optimistic scenario, median margins could be –1% by the fourth quarter of the year. In a less optimistic scenario, margins could sink to –11%.” By then, half of all hospitals could have negative margins.

Today's News and Commentary

About the public’s health

FDA gives green light on 'pool testing' to increase diagnostic capacity: “The Food and Drug Administration (FDA) has issued an emergency use authorization for Quest Diagnostics to begin pooled testing — a testing technique increases capacity, allowing up to four test samples to be tested at once…
Pooled testing is relatively straightforward: If the pooled test comes back negative, then all four samples are negative. If it comes back positive, then each sample is individually tested.”

Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020: There is a lot of information in this CDC-published study. The most important finding may be that researchers “found the highest COVID-19 rate (18.6% [95% CI 14.0%–24.0%]) for household contacts of school-aged children and the lowest (5.3% [95% CI 1.3%–13.7%]) for household contacts of children 0–9 years in the middle of school closure.”

Challenge Trials for COVID-19: 125 scientists signed an open letter to NIH head Dr. Francis Collins highlighting the “vast importance of human challenge trials as a method to help develop vaccines.” They stress the need for properly chosen test subjects and clinical protocols.

Dozens of Florida labs still report only positive COVID tests, skewing positivity rate: “A review of state data shows many small, private labs have been reporting only their positive results to the state -- skewing the positivity rate higher. 
Even after this issue came to light… several dozen labs are still reporting 100% positivity rates, according to a review of Friday's DOH data.”

Pre-fab vaccine facilities aim to help fill production gap: “The German engineering group Exyte has developed modular Covid-19 vaccine manufacturing facilities that can be delivered within six months, to supply pharmaceutical companies rushing to expand their production sites on the back of encouraging clinical trial data. The Stuttgart-based business, formerly known as M+W Group, has joined forces with Siemens and Belgian group Univercells Technologies to offer bespoke facilities that meet European and US regulations, and can be transported on the back of a lorry.”

About health insurance

Appeals court upholds Trump administration's expansion of short-term plans: “A federal appeals court upheld the Trump administration's expansion of short-term health plans.
A panel of judges for the District Court for the District of Columbia ruled that  while opponents of such plans may be correct that they're a poor option for consumers, the Department of Health and Human Services was within its statutory authority to expand them regardless.”

Hospitals Appeal Decision Upholding Disclosure of Rates Negotiated With Insurers: “The American Hospital Association on Friday appealed a decision upholding a Trump administration rule that requires hospitals disclose the rates they negotiate with insurance companies that aren’t made public.
The trade group argued the rule goes against congressional intent and is based on an unlawful interpretation of federal law, according to its filing with the U.S. District Court Court of Appeals for the District of Columbia Circuit.”

About pharma

AstraZeneca's eagerly awaited COVID-19 vaccine passes large test, but confirmation needed:”As Moderna, Pfizer and BioNTech have this month been busy releasing early data out of their COVID-19 vaccine programs, AstraZeneca is now joining the July data drop…
The trial of the vaccine, known as AZD1222 and being developed by AstraZeneca and scientists at the University of Oxford, was generally safe (fevers and headaches hit the majority but could be controlled), and it saw both antibody and T-cell immune responses.”

Synairgen's inhaled interferon beta cuts chance of developing severe COVID-19 disease:
”Synairgen announced Monday that its inhaled formulation of interferon beta, dubbed SNG001, significantly reduced the chance of developing severe disease compared to placebo in hospitalised COVID-19 patients…According to Synairgen, results showed that the odds of developing severe disease during the treatment period were cut by 79% for hospitalised patients receiving SNG001 compared to those given placebo. In addition, patients who received SNG001 were more than twice as likely to recover over the course of the treatment period versus those in the placebo group.”

Remdesivir: Recommendations for Hospitalized Patients With Severe COVID-19: The NIH updated its recommendations on Friday:

  • “In situations where remdesivir supplies are limited, the COVID-19 Treatment Guidelines Panel (the Panel) recommends that remdesivir be prioritized for use in hospitalized patients with COVID-19 who require supplemental oxygen but who are not mechanically ventilated or on extracorporeal membrane oxygenation (ECMO) (BI).

The following recommendation statements for the use of remdesivir are currently being revised and will be updated soon:

  • The Panel recommends administering the investigational antiviral agent remdesivir for 5 days for the treatment of COVID-19 in hospitalized patients with SpO2 ≤94% on room air (at sea level) or those who require supplemental oxygen (AI).

  • The Panel recommends remdesivir for the treatment of COVID-19 in patients who are on mechanical ventilation or ECMO (BI).”

Possible vaccine protein for COVID-19 made in silkworms: “Kyushu University has used silkworms to develop a protein that could become a candidate vaccine for COVID-19, with the hope of starting clinical research for the vaccine as early as fiscal 2021… the vaccine could be mass-produced at an ‘insect plant,’ keeping down the cost per inoculation to only several thousand Japanese yen.” [The Yen is trading at about 107/1US$]